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Abstract 
 
Introduction  
Pseudomonas aeruginosa is a virulent pathogen.  It can exist both in the environment and the 
human host.  Recent work by Turner et al suggests that it is the environment that P. aeruginosa 
exists that determines the virulence factors that are expressed [1].   
P. aeruginosa bloodstream infections (BSI) are predominantly seen in the hospital or healthcare-
associated host [2-5].  This BSI is no longer the rare entity of the original case series in the 1950’s, 
with increasing prevalence over the subsequent decades [6, 7].  The associated morbidity and 
mortality with this infection is considerable [2, 8-10].  This has not improved over time [7].   
The antibiotic treatment options available, in the current age of global antibiotic resistance, has not 
kept pace.  A mortality benefit of combination antibiotic therapy in the setting of P. aeruginosa BSI 
has not been consistently shown [11-17].  In the settings of drug resistance or the 
immunocompromised host, more effective ways to utilise current antibiotic therapy must be 
considered.   
It is therefore timely that we further characterise the clinical and molecular epidemiology, virulence 
genotype and outcome of P. aeruginosa BSI.   
 
Methods 
BSI episode data was collected retrospectively over a three-year time period from the first of 
January 2008 to the first of January 2011.  This involved seven tertiary care institutions, servicing 
an urban population of 2.24 million.  Extensive epidemiological, clinical, laboratory, treatment and 
outcome data was collected as per a pre-formulated data collection sheet (Appendix A).  For 
purposes of the study on BSI in the setting of febrile neutropenia, data was collected from a single 
institution over an extended period of time from the 1st of January 2006 to the 1st of April 2014. 
Ethics approval was obtained from each of the study sites. 
A P. aeruginosa BSI isolate collection was also collated for study. This involved five public and 
private laboratories. Isolates were collected from the time period of the first of January 2008 to the 
first of January 2013. The laboratories service eight tertiary care institutions and one secondary care 
institution.  Permission was obtained from each of the laboratories.  
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Results 
595 P. aeruginosa BSI episodes were characterised from the study centres.  942 BSI isolates were 
collated and analysed as part of the BSI isolate collection.   
A retrospective cohort study of monomicrobial P. aeruginosa BSI described the recent Australian 
epidemiology of this BSI.  The longitudinal mortality of this infection was found to increase with 
time and at one year was greater than would be expected for the comparative death rate predicted by 
the median Charlson’s co-morbidity index (CCI) of the cohort [18].   
Detailed description of a retrospective cohort of community acquired (CAI) P. aeruginosa BSI gave 
new insight into the epidemiology of this group of patients.  Multivariate analysis comparing CAI 
and health-care associated infection cohorts (HCAI) found that CAI is not associated with a shorter 
length of hospital stay, lower mortality rates or less antimicrobial resistance [19].   
Review of patients who developed recurrent P. aeruginosa BSI gave insight into a previously 
uncharacterised cohort of patients.  A recurrent BSI was found to place an individual at an increased 
risk for a further recurrence and had a higher mortality rate than the primary BSI episode [20]. 
Further work into the molecular epidemiology of this cohort revealed that the closer in time BSI 
relapse occurred, the more likely it was from the same clonal type.   
Molecular analysis of P. aeruginosa BSI isolates from a single institution in a non-outbreak setting 
demonstrated unexpectedly a polyclonal population structure [21].  This work points to ongoing 
hospital environmental exposure of the vulnerable inpatient to P. aeruginosa.  Thus raising 
important infection control questions.  
Finally the virulence genes of five BSI isolates associated with rapid death in a non-neutropenic 
host were characterised.  This allowed interpretation of the results in a clinical context. Almost 
complete conservation of the virulence genes studied was seen.   
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Conclusion 
 
Within this thesis unique insights into P. aeruginosa BSI have been obtained.  Looking forward, 
further work on the pathogenesis of the BSI in the human host and how this may potentially 
manifest as longer term mortality is required. Furthermore research looking at the metabolic 
pathways that drive the expression of genotypic virulence is also needed. Both these strategies may 
potentially lead to the development of non-antibiotic treatment options in the patient with a P. 
aeruginosa BSI.  Looking more closely at the transmission pathways of this organism in the 
hospital setting that result in patient colonisation, may allow the implementation of preventative 
infection control strategies. Finally how we utilise the antibiotics we have available, depending on 
the host we are treating, is an area of research that requires ongoing attention.  
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Chapter 1:  P. aeruginosa blood stream infection – what do we know? 
                                            
1.1 Introduction 
This chapter presents the background of current knowledge on Pseudomonas aeruginosa blood 
stream infection (BSI).  Specifically: the clinical and molecular epidemiology, antimicrobial 
resistance and its mechanisms, virulence, clinical outcome of this infection and current treatment 
options.  This information, excluding virulence, was reviewed extensively as part of a published 
article in February 2015: ‘P. aeruginosa: evolution of antimicrobial resistance and implications for 
therapy’ and is summarised in the abstract below [22].  Sections pertaining to ventilator associated 
pneumonia have been removed for the purpose of this thesis.  
“P. aeruginosa is a formidable pathogen in the infection arena.  It is not only able to easily adapt to 
the environment, in which it inhabits, but to colonise and invade the human host to cause serious 
infections. In 2011 it was responsible for 7.1 % of all health care associated infection (HCAI) in the 
USA.  The morbidity and mortality of BSI’s is significant.  On a global scale we have seen the 
development of not only multidrug resistance but also extensive and pan drug resistance in this 
organism.  This is often associated with limited clonal types of which we now have epidemiological 
evidence of spread.   With this have come reduced antibiotic treatment options.  Consideration of 
antibiotic infusions, combination therapy and inhalational therapy has occurred in an attempt to gain 
the upper ground.  Gram-negative resistance has appropriately been described as a global 
emergency”. 
 
 
 
 
 
 
 
 
 
2 
 
1.2 Publication:  Pseudomonas aeruginosa: evolution of antimicrobial resistance and 
implications for therapy (Seminars in Respiratory and Critical Care Medicine. 2015 
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3 
 
Introduction 
 
P. aeruginosa was the equal third most common Gram-negative cause of  BSI  in the Centre for 
Disease Control and Prevention multistate point-prevalence survey of HCAI’s [23].  The morbidity 
and mortality of BSI’s are significant.  This review will focus on BSI particularly the epidemiology, 
mechanisms of carbapenem resistance and the latest evidence regarding treatment for this pathogen.  
 
Clinical Epidemiology 
 
Rates of Infection 
 
The Centres for Disease Control and Prevention found that P. aeruginosa accounted for 7.1 % of 
HCAI’s in the USA in 2011 [23].  It was the equal third most common Gram-negative cause of 
BSI’s.  The European Centre for Disease Prevention and Control 2011 point prevalence survey for 
HCAI’s found a similar figure of 8.9% of all infections caused by P. aeruginosa [24].   
 
Blood Stream Infection 
 
Traditionally P. aeruginosa BSI has been regarded as only a hospital acquired infection (HAI) 
however infections acquired outside the hospital setting have been reported [2, 9].  Al-Hasan et al in 
their unique population based study in the United States found that 78% of the monomicrobial P. 
aeruginosa BSIs were either hospital or health care associated and 12% were community acquired 
[9].  When Marra et al looked at the location of acquisition for HAI’s in an American institution 
with 9 intensive care units (ICU) they found that the BSI originated predominantly in the ICU 
setting [4].  The rates of P. aeruginosa BSI have been shown to increase exponentially across age 
and a male predominance has been found [3, 8-10].  Studies looking at case matched analysis of 
risk factors for P. aeruginosa BSI are few.  Joo et al performed a case control study to look at non 
neutropenic patients with a solid tumor. They found that independent risk factors for this P. 
aeruginosa BSI were the presence of lung cancer and previous antimicrobial therapy [5]. The 
strictness of definition for source of infection varies between studies.   Marra et al required the 
identification of the same isolate from the BSI at a secondary site.  They found that the most 
frequent sources of BSI was the respiratory tract and central venous catheters [4].  Kang et al also 
found other primary sites of infection to be important including pancreatobiliary, urinary tract and 
soft tissue [3].  Chen et al were one of the first groups to identify the pancreatobiliary tract as a 
potential significant source of BSI  [25].  The mortality from a P. aeruginosa BSI is significant and 
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has been found to be up to 42%, depending on the population studied  [10, 26-29].  Risk factors for 
in hospital mortality in P. aeruginosa BSI have been focused upon by Joo et al. They found in their 
population the risk factors of corticosteroid use, nosocomial acquisition, polymicrobial infection, an 
increasing Charlson’s weighted co-morbidity index (CCI)  and intensive care unit care to be 
associated with mortality on multivariate analysis [10].   
 
Epidemiology of Carbapenem Resistance  
 
Laboratory Definitions 
 
Two important changes have been made to the definitions surrounding carbapenem resistance and 
P. aeruginosa that are important to mention in this discussion.  Firstly in 2011 new standardised 
definitions were proposed for multidrug resistant (MDR), extensively drug resistant (XDR) and pan 
drug resistant (PDR) bacteria in response to the variable definitions of these terms in the medical 
literature.  MDR was defined as acquired resistance to at least one agent in 3 or more categories. 
XDR was defined as resistance to at least one agent in all but two or fewer antimicrobial categories 
and PDR was defined as resistance to all agents in all antimicrobial categories [30].   It is important 
to note that MDR is not synonymous with carbapenem resistance.  Secondly in 2012 the Clinical 
Laboratory Standards Institute (CLSI) lowered the breakpoint for sensitivity for carbapenems 
(excluding ertapenem) in P. aeruginosa isolates in the routine laboratory setting. This was in order 
to capture isolates expressing resistance mechanisms in the previously defined susceptible range.  A 
breakpoint of less than or equal to 2mg/L was the new definition of susceptibility to meropenem 
[31].  The current European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines also define an identical susceptibility breakpoint for meropenem and P. aeruginosa [32].  
 
Rates of Carbapenem Resistance 
 
Croughs et al published 13 years of susceptibility data on P. aeruginosa isolates from the intensive 
care units in the Netherlands.  In 2008 8.3% of P. aeruginosa isolates were resistant to carbapenems 
and this had increased to 17% in 2010. This change was statistically significant [33].  Slevoc et al 
looked at all the P. aeruginosa susceptibility trend in 6 French hospitals over 2001 to 2011.  The 
majority of isolates were BSI isolates.  The proportion of carbapenem resistant isolates significantly 
increased over this time to over 25% of the isolates.  The proportion of MDR isolates was 20% in 
2001 and had a non-significant decrease over the time period studied [34]. Turning to the USA, 
Eurofin’s surveillance network database collects routine clinical microbiology data from a 
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nationally representative sample of microbiology laboratories in 217 hospitals [35].  Laboratories 
are included based on their geography and the demographics of the population they serve.  
Zilberberg examined the data on P. aeruginosa isolates originating from pneumonia or BSIs from 
2000 to 2009.   They found a net small rise in MDR P. aeruginosa from 10.7% in 2000 to 13.5% in 
2009 among BSI isolates and from 19.2% in 2000 to 21.7% in 2009 among pneumonia specimens.  
For BSI isolates the likelihood of a MDR isolate originating from the ICU was double that from a 
non ICU location [35].  The USA Healthcare Safety Network found that in in 2009 to 2010 26.1% 
of catheter associated BSIs were MDR [36].   In the data described there is both geographical, 
hospital specific and intra hospital variation.  
 
 Risk Factors for Infection with a Carbapenem Resistant or Multidrug Resistant Organism 
 
Studies utilising a case-control methodology to look at independent risk factors for carbapenem 
resistance have found prior antibiotic use, both carbapenem and non carbapenem antibiotics, to be 
significant [37-39].  The lack of consistent identification of particular antibiotics between studies is 
most likely due to the heterogeneity of the patients being studied, varying antibiotic usage patterns, 
the type of study being performed and the varying sample sizes in the studies.   In the P. aeruginosa 
BSI literature, other identified independent risk factors for carbapenem resistance have included 
transfer from another facility, longer duration of hospital stay, ICU admission, arterial catheter 
administration and higher total white blood cell count measured in the peripheral blood on the day 
of diagnosis [37, 38, 40-42].  Johnson et al published a large retrospective cohort study on P. 
aeruginosa BSI and focused on MDR.  They found previous transplantation, hospital acquired BSI 
and prior ICU admission all independent risk factors for MDR isolates [27].  A large prospective 
observational cohort study by Morata et al found that the independent risk factors for a MDR P. 
aeruginosa BSI were bladder catheterisation and prior steroid or antibiotic therapy use [29].  The 
epidemiology of colonisation or infection varies between clinical settings and is important to have 
knowledge relevant to the patient population in which you practise.   
 
Outcome in the Setting of Antimicrobial Resistance 
 
The complexity and the severity of illness in the patient who develops a BSI makes the teasing out 
of factors effecting mortality difficult.  The effect of P. aeruginosa antibiotic resistance on outcome 
in the setting of BSI has shown variable results. A higher 30 day mortality rate in the setting of 
MDR P. aeruginosa  bacteraemia was seen in the observational studies by Morata et al (32.3%), 
Tam et al (40%) and Lautenbach et al (17.4%) [29, 38, 43].  However no significant difference in 
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mortality was seen in P. aeruginosa BSI caused by either carbapenem resistant or MDR P. 
aeruginosa in four further studies [27, 41, 44, 45].  Specifically in the MDR P. aeruginosa BSI, 
both lower Charlson morbidity index and a high risk source of the bacteraemia (respiratory tract, 
intra-abdominal, soft tissue) have been found to be independent risk factors for mortality [40, 44].   
Esterly et al stratified carbapenem mean inhibitory concentrations (MIC) for P. aeruginosa BSI 
isolates and looked at mortality.  They showed an independent prediction of mortality with 
increasing MIC [46].   Pena et al in a prospective multicentre observational study also found that 
the impact of resistance on mortality was statistically significant from the fifth day after the onset of 
bacteraemia and reached peak values at day 30 [40]. Suarez et al showed that in the first 48 hours 
after the onset of bacteraemia, those patients with a carbapenem susceptible isolate had a higher 
attributable mortality than those with a carbapenem resistant isolate. However, this was not seen at 
30 days[28].   The observed effect of antimicrobial resistance, in the setting of a BSI, on the length 
of hospital stay is also mixed [27, 29, 38, 45, 47].    
 
Mechanisms of Carbapenem Resistance 
 
P. aeruginosa can develop carbapenem resistance by a number of mechanisms both mutational and 
acquired.  They include alteration in porins, enzyme production and efflux systems. It is also 
possible that modification of penicillin binding profiles may also play a role [48].  There is differing 
selectivity for the carbapenem affected by these mechanisms and more than one mechanism may be 
required for carbapenem resistance to manifest.  Although porin changes are the most common 
cause of carbapenem resistance in P. aeruginosa, the recent predominance of successful clones 
carrying enzymatic resistance, particularly VIM-2, is of global concern.   
 
Porin Changes 
 
The main route of carbapenem entry into Gram-negative bacteria is via the OprD porin which 
functions like a channel.  Mutational loss of the OprD gene and hence loss of this porin is described 
as the most common cause of imipenem resistance in P. aeruginosa [49]. Combination of this porin 
change with overexpression of AmpC, an Ambler class C beta-lactamase, or efflux pump 
overexpression is required for meropenem or doripenem resistance to manifest [50].  The exact role 
of this porin and carbapenem resistance is still unfolding [51].   
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Efflux Pumps 
 
The terminology of the commonly observed efflux pump is a compound of designations for the 
pump, the linker lipoprotein and the exit portal.  The pumps can reduce drug accumulation in the 
bacteria.  There are 5 superfamilies of pumps with the RND family being the most common.  
Several of the pumps share common substrates.  For example when the MexAB-OprM system is 
upregulated this may cause reduction in meropenem susceptibility in addition to fluroquinolone, 
penicillin and cephalosporin susceptibility.  Upregulation of other efflux pump systems for example 
MexCD-OprJ and MexEF-OprN confers resistance to fluroquinolones and some beta-lactams, 
whereas up regulation of MexXY-OprM reduces susceptibility to aminoglycosides and 
fluroquinolones [51, 52].  Efflux pump upregulation can therefore be a potential cause of MDR in a 
P. aeruginosa isolate. 
Metallo-betalactamases 
MBL’s are the predominant group of carbapenemases found in P. aeruginosa.  They confer 
resistance to all of the beta lactams except aztreonam and require zinc ions for their activity.  These 
genes are normally encoded in class 1 integrons along with other resistance determinants. 
Association of the integron with a plasmid or a transposon allows transfer between bacteria. IMP 
and VIM types are the most common MBL’s found in P. aeruginosa.   IMP-1 (for "active on 
imipenem") was the first mobile P. aeruginosa MBL discovered in Japan in 1991 [53] .  Most of the 
IMP types have a defined geographical distribution apart from IMP 1 and IMP 7 [54].   As the 
variants are found they are numbered sequentially.  More recently IMP 43 and IMP 44 MBL have 
recently been described in two MDR P. aeruginosa isolates in Japan [55].  VIM standing for 
"Verona integron-encoded metallo-beta-lactamase"  was first described in 1997 [56].  Of the 41 
VIM types now described many have been found in P. aeruginosa isolates 
(www.lahey.org/Studies).  Again there is mainly a defined geographical distribution of the allotypes 
but VIM 1 and VIM 2 have been seen globally with a predominance of  VIM-2 [54].   Other types 
of MBL’s in P. aeruginosa have been described, SPM-1, GIM-1, AIM-1, and FIM-1 but are not as 
common as the IMP and VIM types [57-59].   NDM-1 was first reported in 2009 by Yong et al in a 
K. pneumoniae isolate from India [60].  Subsequently global dissemination in Enterobacteriaceae 
has been documented which is of major concern [61].  Emergence in P. aeruginosa was 
subsequently documented by Jovcic et al  in Serbia in 2011 [62].  A new zinc dependent intrinsic 
imipenemase, P. aeruginosa 5542, dubed PIB-1 France, has just been identified by Fajardo et al 
[63].   
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Other Beta-Lactmases 
 
The beta-lactamase enzymes are divided into four functional groups A to D.  Much less common 
enzymatic causes of resistance in P. aeruginosa are type A or D beta-lactamases. The class A serine 
carbapenemases described in this bacterium are either GES or KPC types.  They are plasmid 
encoded enzymes and thus potentially transferrable. Not all GES types manifest carbapenemase 
activity in contrast to KPC types.  A second mechanism of carbapenem resistance, such as 
membrane impermeability, must be present for imipenem resistance to be manifested in the setting 
of the GES 2 enzyme.  GES and KPC enzymes have been described worldwide. However GES 
enzymes are less prolific.  KPC enzymes are more typically described in Enterobacteriaceae but 
have more recently also been described in P. aeruginosa [64].   Martinez et al recently published a 
case report of a P. aeruginosa isolate co-harbouring KPC-2 and an IMP-18 carbapemenase [65].  
Oxacillinases or class D enzymes are common in P. aeruginosa but their spectrum is such that 
carbapenems are not normally a substrate.  Only two OXA enzymes OXA 40 and 198 have been 
described in isolated reports to express carbapenemase activity [66, 67]. 
 
Molecular Epidemiology  
 
P. aeruginosa has been shown in general to have a non-clonal population structure.  Recombination 
plays a large part in the diversity of the bacterial isolates.  When a range of clinical and wider 
environmental isolates were studied it was shown that clinical P. aeruginosa isolates are 
genotypically indistinguishable from environmental isolates.  Isolates from the same clone can be 
found from different habitats separated by large geographical distances [68-71].  In this context  a 
multiclonal outbreak of P. aeruginosa BSI has been described in the literature [72].  There is 
however the punctuation by highly successful epidemic clones or clonal complexes.  This has been 
traditionally described in the CF patient population where it is not associated with MBL’s [73]. The 
successful clones seem to be geographically isolated and have been attributed to random 
recombination and subsequent local transmission [68, 71].   In the non CF setting early studies 
regarding carbapenem resistance showed no evidence of clonality [74]. Since then the published 
literature on antibiotic resistant isolates has shown that the majority of isolates belong to a few 
successful clones such as ST 111, ST175 or ST235.  This has been seen worldwide [75-79].  It is 
felt to reflect the ability of these particular clones to acquire genetic resistance mechanisms.  
However, the study by Edelstein et al now provides longitudinal data showing evidence of cross 
transmission of these clones, thus contributing to the spread of  resistance [79]. 
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Treatment: Blood Stream Infection 
  
Empirical Therapy 
 
Since 1958, when colistin first became available, the range of antibiotics against P. aeruginosa has 
increased.  We have also developed a better understanding of how to use such drugs.  Gentamicin 
monotherapy for P. aeruginosa BSI,  for example, is no longer considered adequate [80].  There are 
many treatment studies published regarding empirical therapy in the setting of P. aeruginosa BSI.  
Comparison of these observational studies is inherently difficult due to variance in factors such as 
patient populations, study methodology used, critical definitions, antibiotic resistance rates and time 
to appropriate therapy.  Morata et al on analysis of their prospective single centre cohort of  P. 
aeruginosa BSI, were able to show that inappropriate empirical therapy itself was an independent 
risk factor for 30-day mortality regardless of the susceptibility pattern [29].  Appropriate therapy 
being defined as utilisation of at least one effective antimicrobial based on in-vitro susceptibilities.  
However conflicting results have been obtained regarding appropriate empirical therapy and 
mortality benefit [3, 13, 15, 29, 81, 82].  A recent study by Schechner et al focused on mortality in 
P. aeruginosa BSI.  They looked at patients who were found to have a BSI within 72 hours of 
hospital admission.  The majority of infections were healthcare associated.  They did not find 
inadequate empirical antimicrobial therapy was a risk factor for mortality on multivariate analysis.  
On subgroup analysis with sepsis severity at presentation stratified, in the severe sepsis group 
inadequate empirical therapy had a relative risk of mortality of 1.8 (CI 1.1- 2.8, p=0.051).  This was 
not statistically significant [26].   Identification of the patient groups who would most benefit from 
appropriate empirical therapy is still to occur.  Recent studies have focused on treatment in the 
setting of antimicrobial resistance.   MDR has been shown to be associated with a patient being 
more likely to receive inappropriate empirical antibiotic therapy [28, 29, 43, 83].   
 
Definitive Therapy 
 
Turning to the comparisons of definitive therapy in the literature, despite the limitations described 
above, a mortality benefit of definitive treatment with an effective antimicrobial has been shown 
more consistently [13, 14, 16, 45].  Vidal et al found that inappropriate definitive therapy became an 
independent risk factor for death, only when the subset of patients with intravenous catheter 
associated bacteraemia were excluded from the analysis. They hypothesized that this was due to a 
removable focus making the benefit of antibiotic therapy less easy to show [12].    The concept of 
using the mean inhibitory concentration (MIC) of a beta-lactam antibiotic for a bacterial isolate to 
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help guide dosing of that antibiotic has been increasingly explored.  This is the minimum 
concentration of antibiotic that is required to inhibit the growth of the organism in vitro. We would 
expect appropriate antibiotic dosing to achieve antibiotic concentrations above the MIC for the 
sensitive bacterium. The role of achieving antibiotic concentrations above the MIC for longer time 
periods by dosed bolus administration or an infusion is a subject of interest.  Lodise et al published 
one of the earlier studies utilising piperacillin-tazobactam infusions for P. aeruginosa infection.  
The main source of infection in the patients studied was the respiratory tract.  They aimed to obtain 
a free drug concentration exceeding the MIC for 50% of the dosing interval for the range of MIC’s 
in a susceptible P. aeruginosa isolate. By Monte Carlo simulation this was found to be best 
achieved by a 4 hour infusion of 3.375g eighth hourly.  One hundred and ninety four patients were 
included in the study and they found that in patients with an Acute Physiological and Chronic 
Health Evaluation Score of greater than 17, that 14 day mortality was significantly lower.  They 
also found that there were significant benefits on median length of hospital stay, defined from time 
of collection of the index blood culture [84]. Dulhunty et al focused on the ICU setting and 
conducted a prospective multicentre double blind concealed randomised controlled trial in patients 
with severe sepsis.  Sixty patients were enrolled and the study directly compared the effects of 
continuous and intermittent administration of beta-lactam antibiotics.  They found that continuous 
administration achieved significant pharmacokinetic separation in time above the MIC.  The study 
was not powered to look at survival. The end point of clinical cure, defined as clinician determined 
resolution of signs and symptoms of infection, was found to be significantly higher in the infusion 
group despite the power limitations mentioned [85].  Further studies are planned.  Taccone et al 
presented a case report of an XDR P. aeruginosa BSI causing septic shock.  In the setting of drug 
resistance they administered meropenem to achieve levels four times above the MIC of the isolate 
for 40% of the dosing interval. The patient recovered [86].   Further studies in this area are required. 
 
Definitive Therapy in the Setting of Antibiotic Resistance 
 
In the setting of MDR there are reduced antibiotic options which have led to review of older drugs 
such as the polymyxins and fosfomycin.  These drugs would be generally utilised in this setting as 
part of an antibiotic combination.  The polymyxins, colistin and polymyxin B were initially 
discarded due to neuro and nephrotoxicity [87]   Falagas et al looked at a single centre cohort of 
MDR Gram-negative infections treated with colistin.  Twelve percent of the infections were BSI’s 
and 26.4% of the infections were due to P. aeruginosa.  Of the 12 P. aeruginosa infections that 
received monotherapy, nine were cured [88].  Comment cannot be made on the combination 
regimens containing colistin as the definition of MDR meant that prescribed therapy may have 
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consisted of two active agents.   Paul et al subsequently conducted a large single centre prospective 
study of all patients with a MDR Gram-negative bacterial infection.  This study in comparison had a 
higher rate of bacteraemias, only monotherapy and a comparator arm.  Only infections caused by 
isolates susceptible to colistin, carbapenems or ampicillin-sulbactam were included.  The treating 
physician chose the antibiotic regimen and in analysis the beta-lactam therapies were used as a 
control group.   The unadjusted 30 day mortality rate was 39% in the colistin group versus 28.8% in 
the comparators.  This was statistically significant (odds ratio 1.58 (1.08 – 2.31), p = 0.018).  It is 
important to note that the patients treated with colistin had several poorer prognostic features as 
compared to those treated with alternative antibiotics.   Colistin was an independent risk factor for 
renal failure [89].   Park et al conducted a retrospective cohort study, at a single centre, and focused 
on the treatment of monomicrobial P. aeruginosa or A. baumannii bacteraemia.  Eighty one of the 
149 episodes studied were due to P. aeruginosa.  Very few patients in the study received 
combination therapy.  Seventy three patients received appropriate empirical therapy and 9 patients 
in total received colistin. Seven of the nine patients were dead at day 14.  On multivariate analysis 
adequate colistin therapy was a risk factor for mortality [90].  Unfortunately the non randomised 
nature of the studies described does not allow for adequate control of confounding.  Further 
randomised controlled trials are required to further look at colistin’s efficacy and safety.  
Fosfomycin was first available for use in 1973 and now has been revisited particularly in the setting 
of XDR or PDR Gram-negative bacteria.  The geographical variation in fosfomycin resistance has 
been described.  Falagas et al on review of studies looking at resistance rates found a range from 50 
to greater than 90% susceptibility [91].  Limited literature regarding the drug in the treatment of 
BSI’s is published.  Dinh et al prospectively followed a cohort of patients treated with intravenous 
fosfomycin.  Of these, 9 patients with a bacteraemia were reported.  Of these two were caused by P. 
aeruginosa. The majority had a concomitant antibiotic.  Four patients had a favourable outcome, 3 
unfavourable and 2 insufficient follow up [92].  Pontikis et al in a multicentre ICU study 
prospectively followed all fosfomycin treated patients who were XDR or PDR and fosfomycin 
susceptible.  Combination therapy with colistin was used.  Of the 18 primary bacteraemias 11 were 
successfully treated.  In the entire cohort fosfomycin resistance developed in 3 cases.  The main 
adverse event was reversible hypokalemia [93].  The drug itself has attractive pharmacokinetic (PK) 
characteristics, with good distribution into many tissue and body fluids including cerebrospinal 
fluid and lung tissue [94].  The development of resistance to fosfomycin during therapy is one of the 
main concerns regarding utilisation of this drug in the setting of MDR.  
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Combination Therapy 
 
Combination therapy was first looked at in the setting of Gram-negative bacterial studies where 
better overall outcomes were shown [95, 96].  It is difficult to extrapolate these studies to practice 
today as there were small numbers of P. aeruginosa infections in the cohorts and the antibiotics 
used have less intrinsic activity against P. aeruginosa than the agents we use today.  In latter studies 
focusing on P. aeruginosa BSI, antibiotic combinations normally consisted of a beta-lactam with an 
aminoglycoside or fluroquinolone.  Observational studies looking at definitive therapy have failed 
to find a benefit of combination therapy over monotherapy [11-14, 16, 97].  The heterogeneity of 
these studies has previously been discussed.  Contrasting results regarding the benefit of such 
therapy in the empirical setting have been seen [16, 27].  Three studies in 2013 were published on 
this topic.  Bowers et al looked at empiric combination therapy versus monotherapy for P. 
aeruginosa bacteraemia.  They performed an international multicentre retrospective cohort study of 
384 patients.  They did not find on multivariate analysis that combination therapy was significantly 
different to monotherapy in regards to the endpoints studied [98].  Pena et al looked at both 
empirical and definitive therapy and performed a post hoc analysis of prospectively collected data.  
Five hundred and ninety three patients were analysed.  They found no significant difference 
regarding outcome regarding the utilisation of single or combination drug therapy [99].  The lack of 
benefit of combination therapy was again reflected in Hu et al’s meta-analysis of studies on this 
topic [100]. 
Why has research continued in this area? There are many postulated benefits of combination 
therapy.  Micek et al found that appropriate initial antimicrobial therapy was administered 
significantly more often among patients receiving combination therapy than monotherapy.  This 
was in the setting of limited antibiotic resistance [15].  MDR has also been shown to be associated 
with a patient being more likely to receive inappropriate empirical antibiotic therapy [28, 29, 43, 
83].   It is postulated that combination therapy would reduce this occurrence. Drug synergy is 
another postulated benefit.  Studies utilising checkerboard testing, time kill assays or E tests among 
various antibiotics have shown synergy [101, 102].  As surmised by Traugott et al, clinical 
correlation of this testing is not clear [103].  Dias Siqueira et al looked at morphological changes on 
a MDR P. aeruginosa clinical isolate and found summation of the effects in the setting of 
meropenem and ciprofloxacin combination therapy [104].  Combination therapy has also been 
found to be synergistic in pharmacodynamics (PD) models in regards to P. aeruginosa kill rate 
[105].  Prevention of the development of resistance is another postulated benefit.  In the mouse 
model, prevention of the development of resistance in P. aeruginosa has been shown with the 
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combination of tobramycin and cefepime, and meropenem and levofloxacin [105, 106].  The 
utilisation of such therapy must be weighed up against increased expense in comparison to 
monotherapy, the potential for additional or additive drug toxicity and the risk of acquiring another 
MDRO (multi-drug resistant organism).   
The clinical question remains if there is a target population that we have not yet defined in clinical 
studies that would benefit from combination therapy. There were two studies published in 2010 by 
Kumar et al which suggest this might be the case.  The first study was a retrospective cohort study 
and then the second a meta-analysis that showed an independent survival benefit in the setting of 
combination antibiotic therapy for bacterial infection causing septic shock [107, 108].  Further 
studies are required.  The literature behind the utilisation of colistin or fosfomycin in an infection 
that has limited treatment options has already been discussed.  In the setting of drug resistance 
combination therapy may be utilised for the postulated benefits mentioned.   Other agents that are 
often considered are carbapenems, aminoglycosides and rifampicin.   The evidence for utilisation of 
additional agents is mainly based on preclinical studies, case reports or limited numbers of cases in 
a wider cohort.  Paul et al performed a comprehensive review of colistin monotherapy versus 
combination therapy in the setting of carbapenem resistant Gram-negative bacteria.   They did not 
find any benefit on all-cause mortality of the utilisation of combination therapy [109].  Further 
research to guide management in this setting is urgently required.   
Conclusion  
 
P. aeruginosa BSI occurs in the sick host and causes high rates of mortality.  Drug resistant isolates 
are an everyday reality for many hospitals and we now have evidence of the ability of certain 
resistant clones to spread by cross-transmission.   We are attempting to treat resistant infections 
from a small evidence base and with the threat of limited new drugs on the horizon.  Further studies 
looking at how we can better use our existing antibiotic armamentarium are required and the quest 
for new antibiotics needs to be fully supported.  
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1.3 Update on P. aeruginosa blood stream infection  
 
Virulence 
Improving technology and decreasing cost of whole genome sequencing (WGS) has enabled this 
technique to be used more routinely in the research setting.  This has allowed a greater 
understanding of the genome of P. aeruginosa. Mosquera-Rendon et al reported on the pangenome 
characterisation of 200 P. aeruginosa bacterial genomes.  They found that approximately 60% of 
the P. aeruginosa genome was variable across the strains [110]. In this accessory genome, Pohl et 
al identified genes from other bacterial species [111].  Valot et al updated the knowledge of core 
genome of this pathogen by studying 17 sequenced isolates.  Focusing on virulence genes, it was 
found that approximately 2/3rds of the virulence genes were found in the core genome. The 
remainder being found in the accessory genome [112].  
The traditional view of P. aeruginosa pathogenicity was that virulence factors were the most 
important factors in the infective process.   Sentinel work by Turner et al involving translation 
research in mouse models has changed the thinking relating to virulence [1].  This study combined 
both mutant fitness profiling and transcriptome profiling to study which P. aeruginosa genes were 
important for acute or chronic infections.  For most classes of genes, including virulence genes, this 
analysis found that there was little association between transcript abundance and the contribution of 
the corresponding gene towards overall fitness.  However for certain metabolic genes these factors 
were strongly associated [1].  It would seem that it is the environment that P. aeruginosa finds itself 
in that drives the metabolic pathways and expression of virulence factors as part of a process of 
survival.   
The type three secretion system (TTSS) initially came to attention when found to be associated with 
poorer clinical outcomes in the setting of ventilator associated pneumonia [113].  There has been 
recent work in the setting of BSI.  Pena et al looked at a large cohort of BSI of which they also had 
clinical data.  They were able to show that the genotypic presence of Exo U, one of the TTSS 
genotypes, was significantly associated with early patient death [114].  Reboud et al have 
subsequently described another toxin in a hypervirulent strain of P. aeruginosa.  This was called 
ExlA and induces plasma membrane rupture in host cells [115]. In 2016 Wood et al also described a 
type two toxin/anti-toxin system in P. aeruginosa consisting of the proteins HigB and HigA. The 
role of this system is to regulate bacterial toxicity [116].   
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Treatment 
In 2009 the Infectious Diseases Society of America (IDSA) called upon the Obama administration 
and the European Union to help achieve the goal of bringing to the market 10 new antibiotics within 
the following 10 years to treat resistant bacterial infections. To quote the IDSA President Richard 
Whitley:  “The ‘10 x ’20 Initiative’ must succeed in creating a stable research infrastructure for 
antibiotic development; otherwise, physicians around the world will be left without the tools they 
need to effectively treat patients.”  The fruition of subsequent antibiotic development has been 
reflected in the current literature with publications on newly developed antibiotics.   
Ceftolozane-tazobactam is a novel anti-pseudomonal beta-lactam/beta-lactamase inhibitor 
combination that has activity against carbapenem resistant P. aeruginosa caused by porin changes 
or efflux pumps.  Resistance can however be mediated by hyper production of an Amp C 
cephalosporinase.  Antimicrobial activity was tested against 2919 P. aeruginosa isolates collected 
from 13 European countries and Turkey and Israel.  Ceftolozane-tazobactam was the most active 
beta-lactam agent tested against P. aeruginosa isolates [117].  Similar findings were shown by 
Farrell et al who studied P. aeruginosa isolates from US medical centres [118].   The drug has been 
found to have good safety and tolerability in phase three studies [119, 120].  There are no 
randomised clinical trials to guide treatment in the setting of BSI.  Caston et al published 
retrospectively on their experience of the utilisation of this drug in the setting of MDR P. 
aeruginosa infections.  Five of the 12 patients described were bacteremic.  The source of infection 
was either respiratory, abdominal or line related.  Four of the five patients survived [121].    
Ceftazidime-avibactam is another beta-lactam/beta-lactamase inhibitor combination that is active 
against carbapenem resistant, non carbapenemase producing P. aeruginosa isolates.  The avibactam 
component prevents hydrolysis of ceftazidime by Ambler class A, C and several class D enzymes.  
In a phase 3 trial it was found that there were more cases of nausea, vomiting and abdominal pain in 
the group given ceftazidime-avibactam and metronidazole.  However metronidazole may also be 
the cause of these side effects. There are no published reports of treatment of a P. aeruginosa BSI 
with this agent [122].     
Aztreonam-avibactam is another promising beta-lactam/beta-lactamase inhibitor combination that is 
active against carbapenemase enzymes. Aztreonam is however potentially hydrolysed by class A 
and class B beta-lactamases.  Testing of the combination against a global collection of P. 
aeruginosa isolates showed that 44% of 118 MBL positive P. aeruginosa isolates were susceptible 
to aztreonam using CLSI breakpoints [123].  A phase one trial revealed minimal adverse effects 
[124].  Finally Plazomicin, a next generation aminoglycoside, is another antibiotic that has also 
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showed promising activity against MBL producing P. aeruginosa isolates.  This drug has been 
developed to counteract all clinically relevant aminoglycoside modifying enzymes.  Plazomicin was 
found to have good in-vitro activity against 593 P. aeruginosa isolates tested from Canadian 
hospitals [125].  Safety of the antibiotic has been investigated in phase one trials.  Cass et al found 
that adverse events were mild to moderate and included headache, dizziness, somnolence and 
blurred vision.  All adverse effects rapidly resolved. No evidence of nephrotoxicity or ototoxicity 
was observed [126].  
 
1.4 Research program within the thesis 
The research programme presented in this thesis aims to explore interlinking aspects of P. 
aeruginosa BSI.  The programme starts with a review of the background knowledge relating to this 
BSI in Chapter one.  Chapter two describes the recent Australian epidemiology of this BSI with a 
retrospective multicentre cohort study.  It also focuses upon the longitudinal mortality in the setting 
of a P. aeruginosa BSI. This leads to the question of whether we are dying from or with this 
infection?    
Chapter three characterises two P. aeruginosa BSI cohorts in whom there is little knowledge: 
community-acquired P. aeruginosa BSI and recurrent P. aeruginosa BSI.  It is clear from this work 
that the clinician should not be falsely reassured by community-acquisition of this BSI.  The 
epidemiology of recurrent P. aeruginosa BSI is expanded upon in Chapter 4 with characterisation 
of the molecular epidemiology of recurrent BSI.  Subsequently the molecular epidemiology of P. 
aeruginosa BSI in the non-outbreak setting is investigated.  This has important infection control 
implications.  
The investigation of genotypic virulence in P. aeruginosa BSI isolates that caused early patient 
death is presented in Chapter 5.  This is on the background of the significant rates of mortality 
described in previous chapters of the thesis.  This study utilises WGS to provide an in-depth study 
of genotypic virulence.  Finally in chapter 6 future directions of research on P. aeruginosa BSI are 
discussed.  
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Chapter 2:  The current epidemiology of P. aeruginosa blood stream infection 
 
2.1 Introduction 
Werth et al retrospectively studied the incidence of P. aeruginosa septicaemia in hospitalised 
patients.  They found that since 2001 the rates have continued to rise [7].   This is not without 
economic cost [127]. The characterisation of the recent epidemiology of the patient population with 
P. aeruginosa BSI allows us to further knowledge regarding this condition.  This has implications 
for empirical antibiotic therapy regimens.  It also allows us to answer the question whether 
traditional risk factors for this BSI still apply.  Also are there risk factors that can be modified to 
reduce a patient’s risk of infection?  
The mortality rate of P. aeruginosa BSI has also not significantly changed since the mid 1990’s [7].  
Studies looking at the outcome of this infection have focused on the mortality rate out to one month 
post infection.  Nielsen et al published a sentinel paper on the longitudinal mortality of all-cause 
BSI. They described an increasing mortality rate out to 12 years post a BSI.  P. aeruginosa BSI’s 
only made up a small percentage of the BSI’s studied [128].  In a retrospective multicentre cohort 
study we sought to answer the question: Would increasing mortality still be seen with time in 
infection by a highly virulent pathogen?    
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Abstract 
 
Introduction 
P. aeruginosa BSI’s are associated with substantial short term mortality.  There is little data on long 
term mortality in this infection.  The aim of this study was to describe mortality rates out to one 
year post infection and the significant factors associated with death.   
 
Methods 
Positive blood cultures for P. aeruginosa were identified retrospectively from January 2008 to 
January 2011 at 7 tertiary care hospitals.  Extensive epidemiological, clinical and outcome data 
were obtained.   
 
Results 
Three hundred and eighty eight BSI episodes were included in the analysis. The majority of 
infection was hospital-acquired.  The most common patient co-morbidities were haematological or 
oncological.   Seventy eight percent of the cohort had a medical device in-situ in the preceding 7 
days.  Sixty one percent of the cohort received adequate empirical therapy.   All-cause mortality 
was 4% at 48 hours, 19% at one month and 38% at one year.  Forty-eight hour mortality was 
associated with a non-HAI, a pulmonary co-morbidity, recent corticosteroid therapy and a Pitt 
bacteraemia score of greater than 2.  Co-morbidities became significantly associated with mortality 
from 7 days post infection.  Long-term mortality (defined as 1 year mortality) was associated with 
female sex, a haematological or oncological comorbidity, a Charlson’s co-morbidity index of 
greater than 2 and recent corticosteroid therapy.     
 
Conclusion 
The exact role of infection, by a highly virulent pathogen, in the cause of death overtime needs to be 
studied further.  It is not clear if we are dying from or with this infection. 
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Introduction 
P. aeruginosa BSI’s are associated with significant morbidity and mortality.  Mortality rates of up 
to 42% have been described, depending on the patient population studied and the time at which 
mortality endpoint is determined [10, 27-29, 129].  The majority of studies focusing on P. 
aeruginosa BSI have only looked at mortality out to one month post infection.  A population based 
study by Al-Hasan et al in 2008 looked at mortality at 28 days and found a mortality of 25.5%.  
This increased to 47.5% at one year [9].   
Nielsen et al looked at the specific cause attributed to death over a 12 year period in all cause 
bacteraemias.  They found a significantly increased all-cause mortality rate ratio out to ten years in 
the patients with a bacteraemia [128].  Davis et al prospectively looked at outcomes to 5 years 
following hospital admission for sepsis using relative survival analysis.  Australian life Tables were 
used as the reference population.  They found that mortality based on cumulative relative survival 
exceeded that of the reference population for the first two years post admission in the whole cohort.  
On multivariate analysis, predictors of excess mortality included being bacteremic which had a 
hazard ratio of 1.67 (1.15-2.42, p<0.05) [130].   
P. aeruginosa only makes up a small number of the infections contributing to the overall cohort in 
the all-cause bacteraemia studies [128, 131, 132].  The exact role of infection from this highly 
virulent pathogen in the cause of death overtime needs to be studied further.  The aim of this study 
was to look at the longitudinal mortality in this infection and the factors associated with death at 
each of the time points studied.   
 
Methods 
 
Study design 
The study was conducted at 7 tertiary care hospitals in Brisbane, Australia. The hospitals range in 
size from 207 to 929 beds.  Together they provide a specialised and broad medical, surgical and 
intensive care for an urban population of 2.24 million.  Positive blood cultures for P. aeruginosa 
were identified over the 3 year time period of January 2008 to January 2011 from the laboratories 
servicing the hospitals. A BSI episode was identified as the 14 day time period from the date of the 
first positive blood culture [133].  Patients were excluded if they met any of the following criteria: 
age less than 18 years, the blood culture growth was poly-microbial (excluding skin flora) or there 
was growth of another significant bacterial isolate from 10 days prior to 14 days after the collection 
of the sentinel blood culture, the patient was not admitted to hospital post blood culture collection, 
21 
 
the sentinel blood culture was not taken at a participating hospital, the patient did not receive 
antibiotic therapy to treat the blood culture isolate, the patient was transferred to another institution 
within 72 hours of the primary blood culture being collected, or the patient’s case notes could not be 
obtained. Episodes of recurrent infection were also excluded from the analysis.   Ethics approval to 
carry out the study from all participating hospitals and laboratories was obtained.  
 
Data Collection and Definitions 
Assessed clinical variables 
The following data was collected from all patient case notes in a retrospective fashion: age, sex, 
origin of infection (hospital, health-care or community acquired), co-morbidities, CCI, invasive 
medical devices in the 7 days prior to the episode, surgery in the 14 days prior to the episode, 
immunosuppressive therapy or blood products in the 30 days prior to the episode, source of the 
bacteraemia, antimicrobial therapy started from 30 days prior to post primary bacteraemia, the Pitt 
bacteraemia score and the length of hospital stay post bacteraemia onset [134, 135].  For 14 days 
from the date of the sentinel blood culture, daily temperature, daily lowest systolic blood pressure 
and if any pressor therapy was used was also recorded.  From the laboratory, details of any other 
blood culture isolates from 10 days prior to 30 days post the episode were obtained. In addition 
antibiograms of the P. aeruginosa isolates of interest, other sites of growth of P. aeruginosa within 
48 hours before or after positive blood cultures for P. aeruginosa and daily white blood cell count 
were recorded.  Mortality data was obtained from either documentation of a patient’s death in the 
case notes, evidence of a patient’s autopsy results on the relevant laboratory database, date of death 
recorded as part of the public hospital discharge summary database across public hospitals in 
Queensland, the Courier Mail funeral notices or from the Queensland Registry of Births, Deaths and 
Marriages.    
 
Definitions 
A bacteremic episode is defined as the 14 day time period from the date of the first positive blood 
culture for P. aeruginosa.  Positive blood cultures outside this time constitute a different episode.  A 
HAI is defined as a positive blood culture obtained from a patient after 48 hours of hospitalisation 
or within 48 hours of discharge.  A healthcare associated infection (HCAI) is defined as a positive 
culture obtained from a patient at the time of hospital admission or within 48 hours of admission if 
the BSI fulfilled any of the following criteria: 1. Is a complication of an indwelling medical device; 
2. Occurs within 30 days of a surgical procedure where the BSI is related to a surgical site infection 
(SSI); 3. An invasive instrumentation with or without an associated procedure, related to a BSI, was 
performed within 48 hours before the onset of infection. If the timing of onset was longer than 48 
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hours there must be compelling evidence that the infection was related to an invasive device or 
procedure; 4. Received therapy with temporary intravenous access in the 48 hours before the onset 
of infection.  If the timing of onset was longer than 48 hours there must be compelling evidence that 
the infection was related to the invasive device or procedure; 5. Associated with neutropenia (< 0.5 
x 109/L) caused by cytotoxic therapy; 6. The patient resided in a nursing home.   A CAI is defined 
as a positive culture obtained at the time of hospital admission or within the first 48 hours after 
admission which does not fit the criteria for a HCAI [136].  Underlying disease refers to all 
conditions present at admission and diagnosed with up to 48 hours of the BSI.  The definition of 
source of infection were modified from Centres for  Disease Control and Prevention definitions 
[137].  The source of bacteraemia was divided into two categories: low risk, including BSI’s of 
urinary tract and vascular catheter origins and high risk including all other sources.  Antibiotic 
therapy was divided into 4 cohorts.  The empirical therapy cohort (ETC) included those patients 
who received an active agent against P. aeruginosa that was considered adequate based on analysis 
of the antibiogram of the isolate causing the infection in each episode.  Beta-lactam/beta-lactamase 
inhibitor therapy (BLBLI) excluding amoxicillin-calavulanate, carbapenem therapy excluding 
ertapenem, ceftazidime, cefepime and ciprofloxacin (intravenous) were considered acceptable.  This 
therapy needed to start within 24 hours of the blood culture being drawn; the antibiotic had to have 
been administered for at least 48 hours, with the single exception of patients who died before 48 
hours, who were included if death occurred after 1 complete day of therapy with the assigned 
regimen.  The targeted therapy cohort (TTC) included patients who received an active agent against 
P. aeruginosa based on the susceptibility profile of the isolate.  Targeted therapy had to have started 
within 5 days of the blood culture being drawn and to be administered for at least 5 days. For 
patients who died while on targeted therapy, only those who died after at least 1 complete day of 
therapy with the targeted regimen were included.  Patients with the above criteria who continued 
with the same therapy that had been administered empirically once susceptibility results became 
available were also included in the TTC.  The utilisation of oral therapy was also looked at by the 
identification of patients who made a rapid change to oral therapy (RCOT) or made a late change to 
oral therapy (LCOT).   The RCOT cohort included any patient who received targeted therapy with 
the above criteria but the targeted therapy included a change to oral ciprofloxacin within the first 5 
days of targeted therapy. The LCOT cohort included any patient who after a minimum of 5 days of 
targeted intravenous therapy had received at least 2 days of oral ciprofloxacin in the second 5 day 
phase of potential antibiotic therapy.  If the patient had been rapidly changed to oral ciprofloxacin 
as per the RCOT cohort they were excluded from this group.  Recurrent infection was defined as 
subsequent culture of P. aeruginosa outside the primary BSI episode.  Mortality referred to all-
cause mortality.  
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Microbiological Methods 
During the study period the blood cultures were processed by the BD BACTEC™ (43003-1) blood 
culture system (BD, North Ryde, Australia) with an incubation period of 5 days.  Isolates were 
identified by the VITEK 2 system (bioMerieux, Balmes-les-Grottes, France).  Antimicrobial 
susceptibility testing was performed by a microdilution method on the VITEK 2 system. CLSI 
breakpoints for each year of the study were used to define susceptibility or resistance to the 
antimicrobial agents tested.   
 
Statistical analysis 
Variables with greater than 10% of missing data were excluded from the analysis to allow inclusion 
of the maximal number of patient episodes in the mortality analysis.  To prevent over fitting of data 
variables with less than 10% of the cohort having the presence of that factor were also excluded.  
The relationship between mortality and categorical variables were compared using the chi-square 
test.  The student’s t test was used for continuous variables.  To identify independent risk factors for 
mortality, variables with a p value of < 0.2 on the univariate analysis were included in a backward 
stepwise multivariate logistic regression model. The variable was also required to make clinical 
sense to be included in the model. The fit of the model was assessed by the standardized Pearson 
test.   The analysis was done using Stata software (version 13; StataCorp LP).  
 
Results 
 
This study retrospectively reviewed 595 episodes of P. aeruginosa BSI from 7 tertiary care 
hospitals in the city of Brisbane, a capital city of Australia, over a 3 year period.  Of the total 
number of episodes, 207 episodes were excluded as they did not fit the defined criteria for 
inclusion: age less than 18 years (6), the blood culture growth was poly-microbial (excluding skin 
flora) or there was growth of another significant bacterial isolate from 10 days prior to 14 days after 
the collection of the sentinel blood culture (132), the patient was not admitted to hospital post blood 
culture collection (8), the sentinel blood culture was not taken at a participating hospital (2), there 
was no antibiotic treatment of the blood culture isolate (4), the patient was transferred to another 
institution within 72 hours of the primary blood culture being collected (4), patient’s case notes 
could not be obtained (21) or an episode of recurrent infection (30).    This left 388 individual 
patient BSI episodes for analysis.  
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Characteristics of the Patient Population with P. aeruginosa BSI 
The clinical and demographic characteristics of the patients are outlined in Table 1.  Sixty percent 
of infections were hospital acquired.  Twelve percent of infections were CAI. Only 5% of the 
episodes involved patients in the ICU at the time of collection of the primary blood culture. The 
majority of patients being in the ward setting at time of specimen collection.  The median CCI was 
2 (range 0-9). Thirty six percent of the patients had a haematological comorbidity, 19% an 
oncological comorbidity and 4% an autoimmune comorbidity.  There were only 26 patients with an 
organ or bone marrow transplant in the cohort. Two hundred and twenty one patients (57%) had 
received medical treatment in the 30 days prior in which the predominant therapy received was 
either chemotherapy or corticosteroids.  Twenty four percent of the cohort had been neutropenic in 
the preceding 14 days and 20% had undergone surgery in the same time period.  Seventy eight 
percent of the cohort had a medical device in-situ in the preceding 7 days of which the most 
common was a vascular catheter followed by an indwelling urinary catheter (IDC). The source of 
infection could only be characterised in 139 of the patients in whom 16% were line related and 54% 
from the urinary tract.   The median Pitt bacteraemia score for the BSI episodes was one.  Only 14% 
of the cohort was still febrile and 14% hypotensive at 72 hours post collection of the sentinel blood 
culture. Twenty seven percent of the 271 patients for which this data could be obtained still had an 
elevated white cell count at 72 hours.   
The isolates of P. aeruginosa were highly sensitive with only 12 episodes containing a multidrug 
resistant isolate [30].  Sixty one percent and 67% of the cohort received adequate empirical and 
targeted therapy according to the study definitions.  Forty seven BSI episodes received early oral 
ciprofloxacin therapy and 47 episodes oral ciprofloxacin therapy in the second five days of the 
treatment course.   
 
Longitudinal Mortality of P. aeruginosa BSI 
Seventeen patients (4%) of the 388 patient cohort with P. aeruginosa BSI had died by 48 hours post 
collection of the sentinel blood culture.  This mortality rate increased over time with 11% of 
patients having deceased at 7 days, 19% having deceased by 28 days and 38% of patients having 
deceased at one year.  Sixty eight of these patients died while in hospital. Table 2 shows the 
variables associated with death on multivariate analysis at each of the time points studied.  At 48 
hours having a pulmonary comorbidity, recent corticosteroid therapy, a non-HAI and a Pitt 
bacteraemia score greater than 2 were the most significant variables associated with death. At one 
year female sex, a haematological or oncological comorbidity, a CCI of greater than 2 and recent 
corticosteroid therapy were associated with death.    
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Table 1: Demographic, clinical and microbiological characteristics of the 388 episodes of P. 
aeruginosa BSI 
 
Variable n (%)
Age, mean (range in years) 65 (19-94)
Gender
Male 223 (58)
Acquistion
Hospital acquired 233 (60)
Healthcare associated 105 (27)
Community acquired 48 (12)
Primary blood culture patient location (n=351)
Intensive care 17 (5)
Ward 227 (65)
Emergency Department 89 (25)
Outpatient Clinic 18 (5) 
Co-morbidities
Central nervous system 74 (19)
Cardiovascular system 219 (57)
Pulmonary 99 (26)
Hepatobiliary 19 (5)
Kidney 70 (18)
Urinary tract 17 (4)
Gastrointestinal tract 86 (22)
Rheumatological 52 (14)
Autoimmune 15 (4)
Skin and soft tissue 19 (5)
Hematological 140 (36)
Oncological 74 (19)
Diabetes 68 (18)
Organ or Bone Marrow Transplant 26 (7)
HIV 0
CCI median (range) 2 (0-9)
Medical device in-situ prior 7 days 300 (78)
CSF Pressure Monitor 1
Tracheostomy 27 (7)
Endotracheal tube 31 (8)
Vascular catheter 248 (64)
PEG 1
Indwelling urinary catheter 121 (31)
Prosthesic Material 69 (18)  
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Table 1 continued 
 
Medical treatment 30 days prior 221 (57)
Chemotherapy 117 (30)
Corticosteroids 130 (34)
TNF blocker 1
Other immunosuppressive therapy 29 (8)
Radiation 8 (2)
Blood Product Transfusion 91 (24)
TPN 10 (3)
Neutropenia prior 14 days 91 (24)
Surgery 14 days prior 79 (20)
Pitt Bacteremia Score median (range) 1 (0-12)
Source of infection (n=139)
Central nervous system 0
Mastoiditis 0
Pneumonia 16 (11)
Intra-abdominal 1
Mucositis 15 (11)
Urinary tract infection 76 (54)
Line related 23 (16)
Musculoskeletal 0
Skin and soft tissue 7 (5)
Surgical Site Infection 1
Bedside Markers 
Temperature at 48 hours (n= 332) 74 (22)
Temperature at 72 hours (n=325) 46 (14)
Hypotension at 48 hours (n=330) 66 (20)
Hypotension at 72 hours (n=326) 44 (14)
Elevated WBC count at 48 hours (n=280) 92 (33)
Elevated WBC count at 72 hours (n=271) 74 (27)
Antibiotic Susceptibility
Ticarcillin-Clavulanate resistant 53 (14)
Piperacillin tazobactam resistant (n=328) 23 (7)
Meropenem resistant 16 (4)
Multidrug resistant isolate 12 (3)
Treatment
    Adequate empirical Therapy (n=346) 212 (61)
    Adequate targeted therapy (n=335) 225 (67)
    Early oral ciprofloxacin therapy (n=330) 47 (14)
    Late oral ciprofloxacin therapy (n=287) 47 (16)
Mortality 
    48 Hours (n=386) 17 (4)
    7 Days (n=385) 43 (11)
    28 Days (n=383) 72 (19)
    1 Year (n=382) 147 (38)
Length of stay in days, mean  (range) 22 (1-332)
In Hospital Death 68 (18)  
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Table 2: Risk factors for mortality in the setting of a P. aeruginosa BSI over time 
 
 
 
 
 
Discussion  
This study showed an increasing rate of death out to one year post sentinel blood culture collection 
for patients who have had a P. aeruginosa BSI.  The percentage of death in our cohort increased 
from 4% at 48 hours to 38% at one year consistent with studies on all-cause bacteraemia 
longitudinal mortality. Early mortality was associated with a non-HAI, a pulmonary co-morbidity, 
corticosteroids in the prior 30 days and a Pitt bacteraemia score of greater than 2. The Pitt score was 
associated with death out to 28 days post infection.   The patient’s comorbidity burden represented 
by the CCI, was significantly associated with mortality at all time points studied from 7 days post 
blood culture collection.” 
The majority of P. aeruginosa BSI studies have focused on all-cause mortality at one month post 
infection and describe mortality rates of up to 42% [10, 27-29, 129].   Our study found that the 
longitudinal all-cause mortality associated with P. aeruginosa BSI increased with time post 
infection. We found a mortality rate of 4% at 48 hours that had increased to 38% at 1 year.  Al-
Hasan et al looked at all-cause mortality  in P. aeruginosa BSI  and found a death rate of  25.5%  at 
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28 days which increased to 47.5% at one year [9].   This supports our findings.  Lillie et al looked at 
all-cause bacteraemia and all-cause mortality out to 3 years post a BSI.  They found that the rate of 
mortality increased from 15% at 30 days to 48.75% at 3 years [131].   
A number of  variables have been found to be associated with mortality at one month post P. 
aeruginosa  BSI infection including increasing age, BSI in the ICU setting, nosocomial acquisition, 
shock on presentation, inappropriate empirical drug therapy, corticosteroid use, high risk source of  
infection (defined as all BSI sources apart from urinary tract, vascular catheter, pancreatobiliary), 
antimicrobial resistance, polymicrobial infection and specific comorbidities such as cancer, 
cirrhosis and human immunodeficiency virus [3, 10, 27, 29, 40, 44, 46, 114, 138].   Early all-cause 
mortality, at 48 hours, in our study on multivariate analysis was associated with a non-HAI, a 
pulmonary comorbidity, recent corticosteroid use and a Pitt bacteraemia score greater than 2.  
Explanation of how these factors could contribute to a death in the acute setting is possible.  
However further out from this period how does one interpret the associations found?  In our study 
the comorbidity burden became increasingly important from 7 days post sentinel blood culture 
collection. A CCI of greater than 2 was found to be significantly associated with all-cause mortality 
out to one year post sentinel blood culture collection.   A haematological co-morbidity, oncological 
co-morbidity and neutropenia within the prior 14 days to BSI were associated with mortality after 7 
days post the BSI.   Corticosteroid therapy in the 30 days preceding BSI was important at 48 hours 
post BSI and then from 7 days onwards posts BSI. Female sex also became significantly associated 
with mortality at one year post the BSI.  It is difficult to distinguish between the variables that are 
independent from infection and those that are directly involved in the pathophysiology of the 
infective process leading to mortality. 
In an attempt to further define the role of infection and control for co-morbidities Leibovici et al 
looked at survival out to 4 years following all bacteraemia or fungemia.  They compared patient 
survival in these patients to a control group without infection.  Each patient in the study was 
matched to a control patient based on age, sex, department and date of hospitalisation and the 
presence and absence of the following co-morbidities:  solid malignancy, haematological 
malignancy, diabetes mellitus, congestive heart failure, chronic or acute renal failure, 
atherosclerotic heart disease, valvular disease, cerebrovascular accident, cirrhosis, cytotoxic 
treatment, burns and multiple trauma.   They found the mortality rate  was significantly higher at 
all-time points assessed, out to four years in the group with infection in comparison to the control 
group [139].  Quartin et al have shown also that sepsis increased the risk of death for up to five 
years after a septic episode even  if comorbidities were accounted for [140].  In our study the 
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median CCI of the cohort was 2.  In the original study by Charlson et al, a CCI of 1 or 2 correlated 
with a death rate of 26% at one year [134]. In our study 38% of the patients had died at one year 
which is above what would be predicted by the median CCI score for the cohort.   
Nielsen et al looked at the specific cause attributed to death over a 12 year period in all-cause 
bacteraemias.  In a population based cohort study they used the Danish cause of death register for 
attribution.   They found a significantly increased all-cause mortality rate ratio out to ten years in 
the patients with a bacteraemia. They found that cardiovascular disease and malignancy were the 
most common cause of death post bacteraemia.  In their cohort an infectious diseases cause of death 
accounted for only 5% of deaths at 0-1 year and 2.1% of deaths after one year [128].   The 
difficulties of clinically defining cause or causes of death to write on a death certificate and its 
inaccuracies when compared to autopsy findings has previously been highlighted [141, 142]. 
It is not clear if patients are dying from or with P. aeruginosa BSI.  Lillie et al in their all-cause 
bacteraemia study looked for associations that may explain the later causes of death.  At 1 year they 
found increasing age and lower serum albumin predictive of death.   At 3 years they found 
increasing age, lower serum albumin, higher urea level and the presence of vascular disease 
predictive of death.  They hypothesized that BSI may be a surrogate marker of risk of death from 
other causes or may precipitate or deteriorate certain disease states such as vascular disease giving 
rise to the rates of  later stage mortality seen [131].  It is important to note that P. aeruginosa only 
made up a small number of the infections contributing to this cohort.   P. aeruginosa is a highly 
aggressive pathogen and it is not known how this would alter the longer term profile of biochemical 
markers discussed.   
Davis et al prospectively looked at outcomes to 5 years following hospital admission for sepsis 
using relative survival analysis.  Australian life Tables were used as the reference population.  They 
found that mortality based on cumulative relative survival exceeded that of the reference population 
for the first two years post admission in the whole cohort [130]. In contrast to patients without 
sepsis, patients with sepsis, in both pre-clinical and clinical studies have demonstrated 
immunosuppressive changes in both adaptive immune system function and antimicrobial immunity 
[143].  Patients discharged from hospital after an episode of sepsis have a high one year mortality 
rate, often due to the development of secondary infection [144]. A such immunotherapies 
potentially reversing the immunosuppressive state are a focus of further investigation [145].  
Future studies in the setting of P. aeruginosa BSI, in the non-septic patient, should ideally utilise 
matching of key variables such as age, sex and co-morbidities for patients to prevent excess 
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attribution of death to infection.  Although prospective studies may allow a calculated assessment at 
the time of death whether infection played a role in the eventual outcome, this is really only 
applicable in the short term setting.  When looking at longer term mortality it may be impossible to 
attribute mortality to infection due to other active co-morbidities that might exist.  A better 
understanding of the pathophysiological mechanism of how a bacteraemia would potentially cause 
long term mortality is also required. This may allow the identification of other indirect laboratory 
markers that can be utilised in future studies.  
There are a number of limitations of this study.  It is a retrospective cohort study and as such has 
potentially hidden biases.  In 21 episodes the case notes could not be obtained and the patients were 
excluded from the study. There was greater than 10% of the cohort with missing data from the 
variables of bedside markers of infection and antibiotic treatment and as such these variables were 
not included in the analysis.  Length of bacteraemia was also not able to be characterised due to the 
almost complete absence of sequential blood cultures in the cohort.  The source of infection was 
only able to be identified in 36% of the cohort and thus was not included in the analysis.  This was 
due to the low rate of source site sampling performed within the specified time period and the strict 
definition of source of infection used.  The breakpoints utilised by the laboratories involved in the 
study were prior to the EUCAST and the CLSI lowering the beta-lactam breakpoints in 2012 [31, 
32]. As such there might be higher rates of resistance than this study has reported according to the 
later version of breakpoints now in use.    
In conclusion the longitudinal all-cause mortality of P. aeruginosa BSI increased over time.  As we 
better understand the pathophysiology of late mortality in the setting of BSI there may be other 
biochemical markers we can utilise to determine the degree to which infection is contributing.  
Long term mortality in the setting of P. aeruginosa BSI needs to be studied further so we can 
determine if we are dying from or with this infection.  
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2.3 Chapter Summary  
This chapter describes the current Australian epidemiology of P. aeruginosa BSI.  The last paper 
studying the Australian population was in 1993 by Chen et al [25]. In comparison to the broader 
epidemiological literature certain key difference were seen in the cohort described.  Firstly CAI was 
seen, a cohort that has not been well characterised in the literature.  In addition the majority of HAI 
originated in patients in the ward and not the ICU setting. This and the increasing rates of HCAI 
could potentially reflect management of sicker patients out of the ICU setting and movement of 
cancer care to the outpatient setting.   The mortality rate in the cohort at 30 days was comparatively 
low.  Low levels of antibiotic resistance were also seen [18].   
This is the first paper in the literature to specifically address longitudinal mortality focusing on P. 
aeruginosa BSI.  It was found to increase with time and was higher than expected for the median 
CCI of the cohort.  It is not clear if the increasing longitudinal mortality found is related to or 
independent from the original BSI [18].  The pathophysiological mechanism by which this might 
occur is also not yet clear and requires further study.  
The concept of community acquisition of this BSI was intriguing.  In an attempt to further 
characterise this cohort of patients further epidemiological work was carried out and is discussed in 
chapter two.  The latter part of chapter three also addresses the epidemiology of recurrent BSI.  In 
epidemiological studies on P. aeruginosa BSI, recurrent infection episodes are typically excluded 
for statistical reasons.  Patients who develop a relapsing P. aeruginosa BSI have not been 
characterised in the literature.  This led to the questions: Is it the same or a modified patient cohort 
at risk for recurrence of P. aeruginosa BSI?  Does a recurrent infection have the same patient 
outcome as a primary BSI?   
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Chapter 3:  Epidemiology of community-acquired P. aeruginosa blood stream 
infection and recurrent P. aeruginosa blood stream infection 
 
3.1: Community-acquired P.  aeruginosa blood stream infection 
 
Publication: Community-acquired Pseudomonas aeruginosa blood stream infection: 
a classification that should not falsely reassure the clinician (Eur J Clin Microbiol 
Infect Dis. 2017 Apr:36(4):703-711). 
 
KL McCarthy1 and DL Paterson1 
 
University of Queensland, UQ Centre for Clinical Research, Brisbane, Australia 
 
Address for correspondence:  Dr Kate McCarthy, University of Queensland Centre for Clinical 
Research, Building 71/918, Royal Brisbane and Women’s Hospital Campus, Herston, QLD 4029. 
(E-mail: kate.mccarthy1@uqconnect.edu.au) 
 
Key Words: Pseudomonas aeruginosa, bacteraemia, blood stream infection, community acquired 
infection, healthcare acquired infection, mortality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
Abstract 
 
Introduction 
P. aeruginosa BSI is predominantly acquired in the hospital setting.   Community onset infection is 
less common.  Differences in epidemiology, clinical features, microbiological factors and BSI 
outcomes led to the separation of bacterial community onset BSI into the categories of HCAI and 
CAI.  Community acquired P. aeruginosa BSI epidemiology is not well defined in the literature. In 
addition it is also not clear if the same factors separate CAI and HCAI BSI caused by P. aeruginosa 
alone.  
 
Methods 
A retrospective multicentre cohort study was performed looking at P. aeruginosa BSI from January 
2008 to January 2011. Strict definitions for HCAI and CAI were applied.  Extensive 
epidemiological, clinical and outcome data were obtained.   
 
Results 
Forty six CAI episodes and 138 HCAI episodes were analysed.  The CAI group could be 
characterised into 10 distinct categories based on comorbidities and clinically suspected source of 
infection.  A pre-morbidly healthy group could not be identified.  On multivariate analysis the 
absence of chemotherapy in the prior 30 days and the presence of a rheumatological comorbidity 
were significantly associated with CAI.  It was not found that CAI had lower rates of mortality, nor 
shorter length of hospital stay than HCAI.   
 
Conclusion 
The clinician should not be falsely reassured regarding outcome by the diagnosis of a community 
acquired P. aeruginosa BSI.   
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Introduction 
Community acquired BSI has recently been divided into two groups, namely HCAI and CAI.  This 
has been based on studies of all cause bacterial BSI’s describing a closer relationship of the new 
HCAI group to HAI in regards to epidemiology, clinical characteristics, microbiological features 
and outcome [146-150].   
Friedman et al primarily described the BSI classification category of health care acquired infection.  
A prospective observation study of clinically significant bacterial BSI’s was performed at 3 
hospitals.  Epidemiological, clinical and outcome features of the patients with BSI were studied.  
They found that the HAI and HCAI’s were statistically more likely to have cancer, an intravascular 
device as a source of BSI, S. aureus as a cause of the BSI and a higher mortality.  This was in 
comparison to community acquired BSI [146].  Valles et al subsequently performed a prospective 
observation cohort study of adult patients with BSI at 3 teaching hospitals.  This study, in contrast, 
included all episodes of BSI including HCAI and CAI in whom the patient was not admitted to 
hospital.  In comparison to CAI, HCAI BSI patients were older, had a worse functional status, a 
higher proportion of catheter related BSI and a higher prevalence of BSI caused by methicillin 
resistant S. aureus.  In addition the rates of crude mortality were higher in the HCAI group [147].  
Kollef et al studied the epidemiology and outcomes of health-care acquired BSI in a multicentre 
retrospective study at 7 US hospitals over a one year period in 2006.  HCAI patients in comparison 
to CAI patients with BSI’s were found to be older, more likely to be male, have a higher mean acute 
physiology score and a greater length of hospital stay.  HCAI represented the majority of all BSI 
presenting for hospitalisation on their cohort [149].       .   
It must be kept in mind that P. aeruginosa BSI’s made up only a small percentage of the BSI’s in 
these cohorts.  Community acquired P. aeruginosa BSI’s are rare and have not been well 
characterised in the literature. The objective of this study is to further characterise such infections 
and to determine if the distinct separation between HCAI and CAI for all bacterial causes of  BSI’s, 
also applies in the setting of  P. aeruginosa BSI’s.   
 
Methods 
 
Study design 
The study was conducted at 7 tertiary care hospitals in Brisbane, Australia. The hospitals range in 
size from 207 to 929 beds.  Together they provide a specialised and broad medical, surgical and 
intensive care for an urban population of 2.24 million.  Positive blood cultures for P. aeruginosa 
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were identified over the 3 year time period of January 2008 to January 2011 from the laboratories 
servicing the hospitals. A BSI episode was identified as the 14 day time period from the date of the 
first positive blood culture. Patients were excluded if they met any of the following criteria: age less 
than 18 years, the patient was not admitted to hospital post blood culture collection, the sentinel 
blood culture was not taken at a participating hospital, there was no antibiotic treatment of the blood 
culture isolate, the patient was transferred to another institution within 72 hours of the primary 
blood culture being collected, the patient’s case notes could not be obtained, the episode of 
infection was hospital acquired or  recurrent.  All CAI episodes with a vascular catheter or an IDC 
within the preceding 7 days were also excluded to reduce any potential misclassification of CAI. 
Ethics approval to carry out the study from all participating sites was obtained.  
 
Data Collection and Definitions 
Assessed clinical variables 
The following data was collected from all patient case notes in a retrospective fashion: age, sex, 
origin of infection (hospital, health-care or community acquired), co-morbidities, CCI, invasive 
medical devices in the 7 days prior to the episode, surgery in the 14 days prior to the episode, 
immunosuppressive therapy or blood products in the 30 days prior to the episode, source of the 
bacteraemia, antimicrobial therapy started from 30 days prior to post primary bacteraemia,  the Pitt 
bacteraemia score, the length of hospital stay post bacteraemia onset and mortality data [134, 135].   
From the laboratory, details of any other blood culture isolates from 10 days prior to 30 days post 
the episode were obtained. In addition antibiograms of the P. aeruginosa isolates of interest, other 
sites of growth of P. aeruginosa within 48 hours before or after positive blood cultures for P. 
aeruginosa and daily white blood cell count were recorded.  The Queensland public hospital 
discharge summary database was also used to also look for a death notification, in addition to the 
patient notes and the laboratory database. 
 
Definitions 
A bacteraemic episode is defined as the 14 day time period from the date of the first positive blood 
culture for P. aeruginosa.  Positive blood cultures outside this time constitute a different episode.  A 
HAI is defined as a positive blood culture obtained from a patient after 48 hours of hospitalisation 
or within 48 hours of discharge.  A HCAI is defined as a positive culture obtained from a patient at 
the time of hospital admission or within 48 hours of admission if the BSI fulfilled any of the 
following criteria: 1. Is a complication of an indwelling medical device; 2. Occurs within 30 days of 
a surgical procedure where the BSI is related to a SSI; 3. An invasive instrumentation or incision 
related to a BSI was performed within 48 hours before the onset of infection. If the timing of onset 
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was longer than 48 hours there must be compelling evidence that the infection was related to an 
invasive device or procedure; 4. Received therapy with temporary intravenous access in the 48 
hours before the onset of infection.  If the timing of onset was longer than 48 hours there must be 
compelling evidence that the infection was related to the invasive device or procedure; 5.  
Associated with neutropenia (< 0.5 x 109/L) contributed to by cytotoxic therapy.  CAI is defined as 
a positive culture obtained at the time of hospital admission or within the first 48 hours after 
admission which does not fit the criteria for a HCAI [136].  Underlying disease refers to all 
conditions present at admission and diagnosed up to 48 hours of the BSI.  The definition of source 
of infection were modified from the Centers for Disease Control and Prevention definitions [137].  
The clinically suspected source of infection was defined as the source of infection based on history 
and clinical examination at the time the treating clinician was notified of the positive blood culture 
result.  The “healthy patient” was defined as: having a CCI of 0, no medical therapy in the 
preceding 30 days, no surgery in the previous 30 days and no neutropenia in the preceding 14 days.  
Adequate empirical therapy was defined as a patient receiving an active agent against P. aeruginosa 
that was considered adequate based on analysis of the final antibiogram of each isolate.  BLBLI 
excluding amoxicillin-clavulanate, carbapenem therapy excluding ertapenem, ceftazidime, cefepime 
and ciprofloxacin (intravenous) were considered acceptable.  This therapy needed to start within 24 
hours of the blood culture being drawn and the antibiotic had to have been administered for at least 
48 hours. If the patient died before 48 hours, they needed to have received 1 complete day of 
therapy with the assigned regimen.  Adequate targeted therapy was referred to as a patient receiving 
an active agent against P. aeruginosa based on the susceptibility profile of the isolate with the drugs 
previously defined as acceptable.  Targeted therapy had to have started within 5 days of the blood 
culture being drawn and to be administered for at least 5 days. If the patient died while on targeted 
therapy, the patient needed to have received at least 1 complete day of therapy with the targeted 
regimen. The patient could receive the same antibiotic empirically and as targeted therapy.   
Mortality referred to all-cause mortality and included analysis of all episodes of infection.  
 
Microbiological Methods 
During the study period the blood cultures were processed by the BACTEC system (Becton 
Dickinson Microbiology Systems) with an incubation period of 5 days.  Isolates were identified by 
the VITEK 2 system (bioMerieux, Balmes-les-Grottes, France).  Antimicrobial susceptibility testing 
was performed by a microdilution method on the VITEK 2 system. CLSI breakpoints for each year 
of the study were used to define susceptibility or resistance to the antimicrobial agents tested.   It is 
important to note that the breakpoints utilised were those  prior to the EUCAST  and the CLSI 
lowering the beta-lactam breakpoints in 2012 [31, 32]. 
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Statistical analysis 
Data from different groups of patients were compared using chi-square test for categorical variables 
and the student t test for continuous variables. If a variable had greater than 10% of the episodes 
missing data, this variable was not included in the analysis.  To identify independent risk factors for 
class of acquisition of infection, variables with a p value of < 0.2 on the univariate analysis were 
included in a backward stepwise logistic regression model.  A ratio of up to 10 outcomes to 1 
variable was used to determine the number of variables in the model. The fit of the model was 
assessed by the standardized Pearson test. The analysis was done using Stata software (version 13; 
StataCorp LP).  
 
ResultsT 
This study included 595 episodes of mono-microbial and poly-microbial P. aeruginosa BSI from 7 
tertiary care hospitals in the city of Brisbane, the capital city of Queensland, in Australia over a 3 
year period.  Two hundred and twenty three episodes were defined as HCAI or CAI.  Thirty nine 
cases were excluded for the reasons of age less than 18 years (1 episode), Emergency department 
(ED) presentation or outpatient presentation only with no hospital admission (6), no active 
treatment of BSI (3), transfer to a non-participating hospital within 72 hours of BSI being identified 
(4) or case notes unable to be obtained (5), recurrent episode of infection (12) and an IDC or 
vascular catheter being in-situ in the 7 days prior to sentinel blood culture collection (11). This left 
184 episodes of infection for analysis.   
Over the 3 year period of the study 46 episodes of CAI met the inclusion criteria.  The 
epidemiological, clinical and laboratory characteristics of these infections are summarized in Table 
3.  The primary blood culture was taken in the ED in 26 (65%) of the 46 episodes of CAI.  This 
group had a mean age of 72 and a CCI of 2 (range 0-8). Cardiovascular disease was the main co-
morbidity, followed by pulmonary disease and then haematological disease. Eighteen of the patients 
had some form of medical therapy in the preceding 30 days, of which chemotherapy was the most 
common.  There were 7 episodes in which the sentinel blood culture was poly-microbial and 1 
episode in which a latter blood culture, within the 14 day episode, grew another organism.  The 
mean Pitt bacteraemia score in the setting of this infection was 1.   
Only 15 episodes of CAI met the strict criteria for source of infection.  There were 5 patients with 
pneumonia, 6 with a urinary tract infection (UTI) and 4 with skin and soft tissue infections.  The 
clinically suspected source of infection was available for 37 of the CAI episodes, as per Table 3.  
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The majority of patients could be grouped into 10 main categories.  The most common suspected 
clinical sources were UTI and lower respiratory tract infection/pneumonia.  In 9 patients there was 
not a clear source suspected clinically at the time the blood culture signalled positive.   
On univariate analysis the variables that were positively associated with a CAI were increasing age, 
a cardiovascular co-morbidity, a pulmonary co-morbidity and a rheumatological co-morbidity as 
per Table 4.  The absence of the following variables was also associated with a CAI: 
haematological co-morbidity, organ or bone marrow transplant, chemotherapy and neutropenia in 
the prior 14 days.  On multivariate analysis a rheumatological co-morbidity and the absence of 
chemotherapy in the prior 30 days were significantly associated with a CAI.   
There were 5 episodes meeting the criteria for the “healthy patient”.  However these patients had 1 
to 3 co-morbidities not captured by the CCI, which by definition was 0.  These co-morbidities 
included hepatitis C, renal calculi, multiple myeloma and the antiphospholipid syndrome.  The age 
range was 35 to 68 with 3 females and 2 males.  The clinically suspected source was intravenous 
drug use (IVDU), UTI lower respiratory tract infection (LRTI)/pneumonia and in one episode it was 
not defined.  All isolates were susceptible to antipseudomonal beta-lactam antibiotics.  The episodes 
are delineated by an asterix in Table 3.  
 
There were low rates of resistance in the CAI and HCAI groups.  In BSI episodes with mono-
microbial infection, only 64% of the CAI episodes received adequate empirical therapy. This is in 
comparison to 78% of patients with HCAI.  The mean length of hospital stay was not statistically 
different between the two acquisition groups. There was no statistically significant difference in 
mortality rates between the two acquisition groups at the time points studied.   
 
Table 3: Community acquired P. aeruginosa BSI patient characteristics and clinically suspected 
source of infection 
 
*RA Rheumatoid Arthritis, IHD Ischemic heart disease, CRI Chonic renal impairment, GORD Gastro-oesophageal 
reflux disease, ARF Acute renal failure, AF atrial fibrillation AAA abdominal aortic anuerysm, COPD Chronic 
obstructive oulmonary disease, CVA cerebrovascular accident, MR mitral regurgitation, OSA obstructive sleep apnoea, 
OA osteoarthritis, PVD peripheral vascular disease, CCF Chronic cardiac failure, AICD Automatic implantable 
cardioverter-defibrillator device, AVR Aortic valve replacement, MVR mitral valve replacement, TVR tricuspid valve 
replacement, CLL Chronic lymphocytic leukaemia, AML Acute myeloid, leukaemia, BMT bone marrrow transplant, 
GVHD Graft verus host disease 
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Table 4:  Comparison of community acquired and health-care acquired P. aeruginosa BSI 
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Discussion  
This study describes the epidemiology and outcome of the rare entity of community acquired P. 
aeruginosa BSI.  The CAI cohort could be divided into ten groups based on epidemiology and 
suspected clinical source of infection: introduced source, obstructed urinary or hepatobiliary tracts, 
UTI, lower respiratory tract infection in the setting of chronic obstructive pulmonary disease, 
chronic leg ulcers, diabetic foot infection, cholangitis, diverticulitis, an immunosuppressed group 
with a variety of clinical sources and unknown clinical source.  A “healthy” group, as defined in the 
paediatric literature, could not be identified.  There was no significant difference in burden of co-
morbidities between the HCAI or CAI groups.  The CAI group was significantly more likely on 
multivariate analysis to have a rheumatological co-morbidity and to not have received 
chemotherapy in the 30 days prior to the BSI.  The CAI cohort was poorly identified at clinical 
presentation as evidenced by only 64% of patients having adequate empirical antibiotic therapy. 
There was no significant difference in rates of resistance between the groups. CAI was not found to 
have a better outcome at 28 days than HCAI, nor reduced length of stay.  The distinct separation 
between HCAI and CAI for all cause BSI’s was not found to apply to P. aeruginosa BSI’s.  
In this study only 46 episodes of P. aeruginosa CAI met the criteria for study inclusion over a 3 
year period, from 7 tertiary care hospitals in Brisbane.  Moon et al were not able to identify a single 
episode in their retrospective review of  community and hospital  bacteraemia over a 5 year period 
in a single tertiary hospital setting in Korea [151].  De Bus et al identified 1 CAI secondary to P. 
aeruginosa over a 2 and ½ year period at  a  Belgian University hospital [152].  At a population 
level  in the Calgary region Parkins et al identified 284 incident cases of  bacteraemia and 21% 
were CAI [153]. The definitions of CAI vary in the literature.  The impetus to change the definition 
of community acquired BSI, through the separation of HCAI BSI, was driven by epidemiological, 
microbiological and outcome factors in all-cause BSI studies.  It was found that HCAI was similar 
to HAI in terms of age, sex, comorbid conditions, source of infection, pathogens, poly-microbial 
infection rates, resistance rates and outcome.  It is important to note that S. aureus and E. coli were 
the predominant bacterial pathogens represented in these studies.   P. aeruginosa BSI, particularly 
CAI, accounted for only a small number of the infections studied [146-150].  
On univariate analysis in this study it was found that the HCAI group in comparison to the CAI 
group was of similar age with no predominance of males in contrast to the all-cause bacteraemia 
studies previously mentioned [147-149].  The HCAI group was also found not to have significantly 
different burden of co-morbidities, as assessed by the CCI, from the CAI group.  The mean CCI was 
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2 and all CAI patients had at least one co-morbidity.  Hattemer et al also did not find a significant 
difference in burden of co-morbidities between HCAI and CAI groups, in the setting of a P. 
aeruginosa BSI [129].   This is in contrast to the findings by Lenz et al and Kollef et al in their all-
cause bacteraemia studies [149, 150].  There were however significant differences on univariate 
analysis between the groups regarding the type of co-morbidity between the acquisition groups.  
CAI patients were significantly more likely to have cardiovascular, pulmonary or rheumatological 
co-morbidities. HCAI patients were significantly more likely to have a haematological co-morbidity 
or an organ or bone marrow transplant.  Fitting with this HCAI patients were also more likely on 
univariate analysis to have had chemotherapy or a blood transfusion in the preceding 30 days and 
suffer from neutropenia in the preceding 14 days.  This is consistent with the findings by Son et al, 
in an all cause bacteremic study,  in which it was found that the HCAI group was more likely to 
have cancer, neutropenia and immunosuppressant therapy [148].  It was the presence of a 
rheumatological co-morbidity and the absence of chemotherapy in the prior 14 days that was 
significantly predicted CAI on multivariate analysis in this study.   
The study’s strict criteria for source of infection were not met in 68% of BSI episodes included in 
the analysis.  This was due to both the low rate of microbiological sampling from the suspected 
source of infection and the requirement that this was done within 48 hours of the collection of the 
sentinel blood culture.  A low rate of definition of the source of infection is not uncommon in 
similar epidemiological studies.  In contract to Lenz et al, this study did not show a significant 
difference in poly-microbial infection between the infection acquisition groups [148]. 
To further characterise the CAI episodes the patient’s age, sex, co-morbidities and suspected source 
of infection by the treating clinician were reviewed in detail.   Nine distinct clinical groups were 
able to be identified:  introduced source, obstructed urinary or hepatobiliary tracts, UTI, lower 
respiratory tract infection in the setting of chronic obstructive pulmonary disease, chronic leg 
ulcers, diabetic foot infection, cholangitis, diverticulitis and an immunosuppressed group with a 
variety of clinical sources.  Introduced source referring to the introduction of a bacteraemia via 
intravenous drug use.  The tenth group was BSI with an undefined clinical source.  The rarity of 
community acquisition of this BSI, its diverse host range and source of infection makes 
identification of this patient group presenting to the emergency department difficult.  In reality it 
may be that it is the emphasis on taking both blood cultures and suspected site of infection cultures 
in the emergency presentation of the febrile patient that will improve the identification rates in this 
group.  A “healthy” group free of co-morbidities with CAI could not be found in our cohort.  In the 
paediatric literature a pre-morbidly healthy group of CAI P. aeruginosa BSI has been identified.   
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Huang et al identified 42 cases of CAI P. aeruginosa sepsis in healthy infants to be associated with 
the presenting symptoms of diarrhoea and fever in Taiwan.   Screening for such disorders was not 
performed in all the patients described in the study [154]. In the adult literature Parkins et al, in 
their previously mentioned population based study, found 9 episodes of CAI BSI in which the 
patient had no comorbidities.  Their cohort included a small number of children and the clinical 
details of these episodes was not provided [153].  Enoch et al, in a retrospective study at two 
general district hospitals on P. aeruginosa BSI, identified a group of 10 patients who had no 
“healthcare contact”.  This was defined as hospital or nursing home contact in the preceding year. 
This group was not however free of co-morbidities [155].   
There was limited antimicrobial resistance in the entire CAI and HCAI BSI cohort described. There 
were three multi drug resistant (MDR isolates) in the HCAI group as per the standardized 
definitions by Magiorakos et al [30]. Despite these high rates of bacterial susceptibility, adequate 
empirical therapy rates were low in both acquisition groups and not significantly different on 
univariate analysis.  In contrast in Son et al’s study on all cause-bacteraemia, the HCAI group had 
significantly lower rates of adequate empirical therapy [148].  This was also found by Valles et al 
[147] .  The lower empirical therapy rate in CAI in our study focusing on P. aeruginosa alone, most 
likely relates to the difficulty in identification of these patients at presentation, excluding those 
patients with a haematological malignancy.   This emphasizes the importance of microbiological 
sampling of the presumed site of the source of infection and the collection of blood cultures in the 
febrile patient. 
There was no statistical difference in the Pitt bacteraemia score between the groups of acquisition in 
our study. Again, this was in contrast to the all-cause bacteraemia study by Son et al [148] . This 
study found that the rates of mortality in the CAI group did not differ significantly in comparison to 
the HCAI group at 72 hours, 7 days or 28 days.  This supports the finding by Hattemer et al in their 
study focusing on P. aeruginosa BSI who found no difference in 30 day mortality between these 
two groups of acquisition and mortality  in their cohort [129] .   All of the four all-cause 
bacteraemia studies previously mentioned showed a significantly higher death rate in the HCAI 
group [146-150].  Parkins et al however found a higher mortality rate in their CAI group of 37% in 
comparison to HCAI at 20%, for P. aeruginosa BSI.   This was attributed to lower rates of adequate 
empirical therapy in this group. There were low rates of MDR and co-morbidities in their CAI 
group studied [153] .   In our cohort the acquisition groups had similar CCI scores, Pitt bacteraemia 
scores, rates of polymicrobial infections, drug resistance and adequate empirical therapy.  This 
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explains the similar rates in mortality seen.  This study also found that length of stay did not differ 
significantly between HCAI and CAI.   
There are a number of limitations of this study.  Firstly it is a retrospective study with potentially 
hidden biases.  There was a large amount of missing data from the variables of bedside markers of 
infection and these variables were unable to be included in the analysis. The length of bacteraemia 
was also not able to be characterised due to the almost complete absence of sequential blood 
cultures in the cohort.  The source of infection was only able to be identified, according to the study 
definition, in 58 episodes of infection.  This was due to the low rate of source site sampling 
performed within the specified time period.  Finally P. aeruginosa BSI is a rare infection and as a 
result the cohort numbers were small.  As such there would have been lack of statistical power to 
assess the true significance of some of the variables assessed in which there were small patient 
numbers afflicted.   
In conclusion this study further characterises community acquired P. aeruginosa BSI.  The patient 
group is clinically diverse with multiple potential sources of infection.  In contrast to the paediatric 
literature a pre-morbidly healthy group could not be identified.  In all cause BSI infection studies 
there is a clear separation between HCAI and CAI groups on univariate analysis in epidemiological, 
clinical and microbiological variables.  The presence of a rheumatological co-morbidity and the 
absence of chemotherapy in the preceding 14 days were the variables that were found to 
significantly differ between the two acquisition groups.  Rates of mortality or length of hospital stay 
were not found to be significantly different between HCAI or CAI groups.  The clear separation 
between CAI and HCAI patients in all-cause bacteraemia studies was not replicated for P. 
aeruginosa BSI.  The clinician should not be falsely reassured regarding outcome by the diagnosis 
of a community acquired P. aeruginosa BSI.   
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3.2: Recurrent P. aeruginosa blood stream infection 
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Abstract  
 
Introduction 
This study aimed to characterise recurrent P. aeruginosa BSI.   
 
Methods 
Positive blood cultures for P. aeruginosa were identified over a three year period from seven 
tertiary care hospitals.  Patients with relapsing BSI were identified.  Extensive epidemiological, 
clinical and outcome data were obtained.  
 
Results 
BSI relapse was found to be uncommon with nine percent of patients having a first relapse of BSI.  
Fourteen percent of these patients went on to have a second relapse of BSI.  Significant variables 
associated with recurrence were the presence of a hematological malignancy or receiving recent 
corticosteroid therapy.  Exposure to anti-pseudomonal beta-lactam therapy in the 30 days prior to 
the BSI was more likely in the patient with the recurrent BSI episode.   
 
Conclusion 
Recurrence was associated with increased mortality when compared to the primary BSI episode.  
Knowledge of a patient’s prior antibiotic therapy may be useful in ensuring effective empirical 
therapy in the recurrent BSI episode.  
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Introduction 
 
The Centers for Disease Control and Prevention found that P. aeruginosa accounted for 7.1% of 
health care acquired infections (HCAI) in the United States in 2011. It was the third most common 
Gram-negative cause of BSI’s [23].  This is an infection with considerable mortality with rates of 
up to 42% being described depending on the population studied [27].  Although primary infection 
has been well studied, cohort studies looking at P. aeruginosa BSI over the last decade have 
typically excluded recurrent infection episodes.   Recurrent P. aeruginosa infection has been 
described in the literature in 3 patient groups: liver transplantation, human immunodeficiency virus 
infection (HIV) and bone marrow or stem cell transplantation patients [156-158]. In clinical practice 
recurrent infection is also seen outside these patient groups. This tertiary multicentre study aimed 
to: a. further characterise the patient in whom a recurrent P. aeruginosa BSI occurs; b. look at time 
to infection recurrence; and c. to characterise the variables that may place an individual at risk for 
recurrence of this infection.   
 
Methods  
 
Study design 
The study was conducted at 7 tertiary care hospitals in Brisbane, Australia. The hospitals range in 
size from 207 to 929 beds.  Together they provide a specialised and broad medical, surgical and 
intensive care for an urban population of 2.24 million.  Positive blood cultures for P. aeruginosa 
were identified over the 3 year time period of 1st of January 2008 to the 1st of  January 2011 from 
the laboratories servicing the hospitals. A BSI episode was identified as the 14 day time period from 
the date of the first positive blood culture.  Patients were excluded if they met any of the following 
criteria: age less than 18 years, the patient was not admitted to hospital post blood culture 
collection, the sentinel blood culture was not taken at a participating hospital, there was no 
antibiotic treatment of the blood culture isolate, the patient was transferred to another institution 
within 72 hours of the primary blood culture being collected, the patient’s case notes could not be 
obtained or the patient died within seven days of the primary BSI episode.   Poly-microbial BSI’s or 
BSI episodes in which another significant pathogen was grown from a blood culture 10 days prior 
to 14 days post the sentinel blood culture collection with P. aeruginosa were not excluded.   
The BSI episodes studied were divided into four groups: a. primary BSI episodes from patients who 
survived 7 days after the initial BSI and did not go on to have a recurrent BSI within the 3 year 
study period; b. the primary BSI episode in a patient who survived 7 days after the initial BSI and  
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that went on to have recurrent infection in the 3 year study period; c. the primary relapse episode of  
BSI in the patient with recurrent infection; and d. any further relapsing BSI episodes in the patient 
that went on to have a further BSI episodes provided they survived 7 days post the preceding BSI 
episode.   The latter group was utilised for descriptive purposes only.  A patient could only be 
represented once within each group. Ethics approval to carry out the study from all participating 
hospitals and laboratories was obtained.  
 
Data Collection and Definitions 
Assessed clinical variables 
The following data was collected from all patient case notes in a retrospective fashion: age, sex, 
origin of infection (hospital, health-care or community acquired), patient location at the time of the 
sentinel blood culture collection, co-morbidities, CCI, invasive medical devices in the 7 days prior 
to the episode, surgery in the 14 days prior to the episode, immunosuppressive therapy or blood 
products in the 30 days prior to the episode, source of the bacteraemia, antimicrobial therapy started 
from 30 days prior to post primary bacteraemia and the Pitt bacteraemia score [134, 135].  From the 
laboratory, details of any other blood culture isolates from 10 days prior to 30 days post the episode 
were obtained.  In addition antibiograms of the P. aeruginosa isolates of interest, other sites of 
growth of P. aeruginosa within 48 hours before or after positive blood cultures for P. aeruginosa 
were recorded, as were periods of neutropenia.  
 
Definitions 
A bacteremic episode is defined as the 14 day time period from the date of the first positive blood 
culture for P. aeruginosa.  Recurrent infection was defined as subsequent culture of P. aeruginosa 
outside the primary BSI episode.   A HAI is defined as a positive blood culture obtained from a 
patient after 48 hours of hospitalisation or within 48 hours of discharge.  A healthcare associated 
infection (HCAI) is defined as a positive culture obtained from a patient at the time of hospital 
admission or within 48 hours of admission if the BSI fulfilled any of the following criteria: 1. Is a 
complication of an indwelling medical device; 2. Occurs within 30 days of a surgical procedure 
where the BSI is related to a SSI; 3. An invasive instrumentation or incision related to a BSI was 
performed within 48 hours before the onset of infection. If the timing of onset was longer than 48 
hours there must be compelling evidence that the infection was related to an invasive device or 
procedure; 4. Received therapy with temporary intravenous access in the 48 hours before the onset 
of infection.  If the timing of onset was longer than 48 hours there must be compelling evidence that 
the infection was related to the invasive device or procedure; 5. Associated with neutropenia (< 0.5 
x 109/L) contributed to by cytotoxic therapy; or 6. The patient resided in a nursing home.   A CAI is 
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defined as a positive culture obtained at the time of hospital admission or within the first 48 hours 
after admission which does not fit the criteria for a HCAI [136].  Underlying disease refers to all 
conditions present at admission and diagnosed with up to 48 hours of the BSI.  The definition of 
source of infection were defined as per modified from Centers for  Disease Control and Prevention 
definitions [137] and line related infections were as per modified Australian Infection Control 
Association guidelines [136] .  A line associated bacteraemia was also defined as a bacteraemia in 
the presence of a central access line in the absence of another source of infection.  Polymicrobial 
infection referred to the growth of another significant bacterial isolate from the sentinel blood 
culture collection in which P. aeruginosa was also identified.   Adequate empirical therapy referred 
to those patients who received an active agent against P. aeruginosa that was considered 
appropriate based on analysis of the antibiogram of the isolate causing the infection in each episode.  
Beta-lactam/beta-lactamase inhibitor therapy excluding amoxicillin-clavulanate, carbapenem 
therapy excluding ertapenem, ceftazidime, cefepime and ciprofloxacin (intravenous) were 
considered potentially appropriate antipseudomonal agents.  This therapy needed to start within 24 
hours of the blood culture being drawn; the antibiotic had to have been administered for at least 48 
hours, with the single exception of patients who died before 48 hours, who were included if death 
occurred after 1 complete day of therapy with the assigned regimen.  Adequate targeted therapy 
referred to patients who received an active agent against P. aeruginosa based on the susceptibility 
profile of the isolate.  Targeted therapy had to have started within 5 days of the blood culture being 
drawn and to be administered for at least 5 days. For patients who died while on targeted therapy 
they needed to have completed at least 1 complete day of therapy with the targeted regimen.  
Patients with the above criteria who continued with the same therapy that had been administered 
empirically once susceptibility results became available were also included.  The utilisation of oral 
therapy was also examined by the identification of patients who made a RCOT or made a LCOT.   
The RCOT cohort included any patient who received targeted therapy with the above criteria but 
the targeted therapy included a change to oral ciprofloxacin within the first 5 days of targeted 
therapy. The LCOT cohort included any patient who after a minimum of 5 days of targeted 
intravenous therapy had received at least 2 days of oral ciprofloxacin in the second 5 day phase of 
potential antibiotic therapy.  If the patient had been rapidly changed to oral ciprofloxacin as per the 
RCOT cohort they were excluded from this group.  Only mono-microbial BSI episodes were 
studied regarding the adequacy of antibiotic therapy.  
 
Microbiological Methods 
During the study period the blood cultures were processed by the BACTECTM system (Becton 
Dickinson Microbiology Systems) with an incubation period of 5 days.  Isolates were identified by 
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the VITEK 2 system (bioMerieux, Balmes-les-Grottes, France).  Antimicrobial susceptibility testing 
was performed by a microdilution method on the VITEK 2 system. CLSI breakpoints were used to 
define susceptibility or resistance to the antimicrobial agents tested.   
 
Statistical analysis 
The relationship between categorical variables was compared using the chi-square test or Fishers 
exact test.  The student’s t test was used for continuous variables.  To identify independent risk 
factors for recurrent infection, variables with a p value of < 0.2 on the univariate analysis were 
included in a backward stepwise multivariate logistic regression model. The variable was also 
required to make clinical sense to be included in the model. Variables with greater than 10% of 
missing data were excluded from the multivariate analysis to allow inclusion of the maximal 
number of patient episodes in analysis of associations with recurrent infection.  To also prevent over 
fitting of data variables with less than 10% of the cohort having the presence of that factor were also 
excluded.  The fit of the model was assessed by the standardized Pearson test.   The analysis was 
done using Stata software (version 13; StataCorp LP).  
 
Results 
This study retrospectively reviewed 595 episodes of P. aeruginosa BSI from 541 patients in 7 
tertiary care hospitals in the city of Brisbane, the capital city of Queensland, in Australia over a 3 
year period. BSI episodes were excluded according to pre-defined study criteria (Figure 1).  This 
left 487 BSI episodes for analysis representing 441 patients.  Over the 3 years of the study, of those 
patients that survived to at least 7 days post the primary infection, 41 of 441 (9%) patients went on 
to have a primary relapse episode of  P. aeruginosa  BSI.  Of the 35 patients that survived to seven 
days post the first BSI relapse episode, a further 5 patients (14%) went on to have a second relapse 
episode of BSI.  Only 2 patients went on to have a third BSI relapse and 1 patient a fourth BSI 
relapse.   The median time to the first relapse episode of infection was 53 days with a range of 15 to 
489 days. The time from the first relapse episode to second relapse episode was a median of 28 days 
with a range of 19 to 33 days.   
The characteristics of the primary BSI in those patients that did and did not go on to have a 
recurrent BSI were compared (Table 5).    On multivariate analysis those patients who went on to 
have a recurrent BSI were significantly more likely to have a hematological malignancy or to have 
received corticosteroids in the preceding 30 days.   The characteristics of the primary and first BSI 
relapse episode in those patients that went on to get a recurrent BSI were also compared to look for 
51 
 
other drivers of recurrent infection (Table 6).  Lack of clinician utilisation of late oral quinolone 
therapy in the first relapse BSI episode was the only variable significantly different on univariate 
analysis between these groups (OR 0.11 (0.013-0.99), p=0.05).   
The rates of antibiotic resistance in the P. aeruginosa BSI isolates in the primary BSI episode and 
the first BSI relapse episode were not found to be statistically different (Table 7).  The patients with 
the first BSI relapse had a significantly higher rate of exposure to anti-pseudomonal beta-lactams in 
the 30 days prior to the BSI. 
To be included in the study all patients had to survive to day 7 of the primary P. aeruginosa BSI 
episode.   Of the patients that survived the primary infection and went on to have a first relapse BSI, 
one of the 40 patients (3%) had died at 28 days after the primary BSI.  Of those patients that 
survived seven days of the primary infection and did not go on to have a recurrent BSI, 28 of the 
378 (7%) patients in whom outcome data was available were dead at 28 days. Thus looking at all 
primary BSI episodes 29 of the 418 (7%) patients in whom outcome was known were dead at 28 
days. In patients that went on to have a first relapse of P. aeruginosa BSI, 7 of the 38 (18%) 
patients were dead at 28 days.  Of the five patients who went on to have a second episode of relapse 
of infection, 2 (40%) patients had died at 28 days post this BSI episode.   
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Figure 1: Study participant flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 Primary BSI episodes 
39 First relapse BSI episodes 
5 Second relapse BSI episodes 
2 Third relapse BSI episode 
1 Fourth relapse BSI episode 
 
87 BSI episodes that represented 41 
different patients that had one or more 
recurrent episodes of P. aeruginosa BSI 
 
BSI episodes excluded from analysis 
(n=108) 
6 - Age less than 18 years 
10 - Outpatient/DEM presentations        with 
no hospital admission 
4 - Sentinel blood culture was not taken at a 
participating hospital 
4 - No antibiotic treatment of BSI 
4 - Transfer to a non-participating hospital 
within 72 hours of BSI being identified 
32 - Patient case notes unavailable 
48 - Patient death within 7 days of primary 
BSI 
  
 
 
 487 BSI episodes representing 441 
patients 
 
595 P. aeruginosa BSI episodes 
from 541 patients 
400 BSI episodes that each represented a 
different patient who had not had 
recurrent episode of   P. aeruginosa BSI 
over the study and had survived 7 days 
post the sentinel blood culture collection 
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Table 5: Comparison of the significant patient and BSI characteristics of the primary BSI 
episode of those patients that did and did not go on to have a BSI relapse 
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Table 6: Patient and BSI isolate characteristics of the primary BSI and the first episode of BSI 
relapse in the host who had a recurrent P. aeruginosa BSI 
 
 
Primary BSI 
episode 
characteristics in a 
patient that has a 
BSI relapse  (n=40)
First relapse BSI 
episode 
characteristics                                   
(n= 39)
Variable n (% ) n (% )
Age, mean (range in years) 62 (25-88) 60 (25 - 87)
Male 20 (50) 20 (51)
Acquistion
Hospital acquired 22 (55) 25 (64)
Health-care associated 15 (38) 12 (31)
Community acquired 3 (8) 2 (5)
Primary blood culture patient location
Intensive care 3 (8) 2 (5)
Ward 23 (62) 21 (54)
Emergency Department 7 (19) 6 (15)
Outpatient Clinic 4 (11) 9 (23)
Co-morbidities
Central nervous system 7 (18) 6 (16)
Cardiovascular system 19 (48) 18 (47)
Pulmonary 5 (13) 4 (11)
Hepatobiliary 0 (0) 0 (0)
Kidney 6 (15) 4 (11)
Urinary tract 1 (3) 1 (3)
Gastrointestinal tract 9 (23) 9 (24)
Rheumatological 2 (5) 3 (8)
Autoimmune 2 (5) 2 (5)
Skin and soft tissue 4 (10) 5 (13)
Hematological 25 (63) 24 (63)
Oncological 4 (10) 5 (13)
Diabetes 7 (18) 7 (18)
Organ or Bone Marrow Transplant 4 (10) 3 (8)
HIV 0 (0) 0 (0)
CCI, mean (range) 1 (0-5) 2 (0-5)
Medical device prior 7 days
Vascular catheter 31 (78) 29 (76)
Indwelling urinary catheter 9 (23) 7 (18)
Prosthesic Material 5 (13) 6 (15)  
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Table 6 continued: 
 
Medical treatment 30 days prior 31 (78) 32 (82)
Chemotherapy 19 (48) 16 (41)
Corticosteroids 24 (60) 19 (48)
TNF blocker 0 (0) 19 (49)
Other immunosuppressive therapy 5 (13) 6 (15)
Radiation 1 (3) 1 (3)
Neutropenia at time of sentinel blood culture collection 9 (23) 16 (41)
Surgery 14 days prior 5 (13) 4 (10)
Pitt bacteremia score, mean (range) 2 (0-8) 2 (0-8)
Source of infection n (%) 35 (88) 34 (87)
Mastoiditis 0 0
Pneumonia 1 3
Intra-abdominal 0 2
Mucositis 0 0
Urinary tract infection 7 2
Line related 20 19
Musculoskeletal 0 0
Skin and soft tissue 7 3
Surgical Site Infection 0 0
Other source 0 5
Polymicrobial Infection or second signiifcant BSI isolate 
10 days prior or 14 days post sentinel blood culture 
collection 9 (22) 8 (21)
Monomicrobial BSI Treatment (n=62)
    Adequate empirical Therapy (n=54) 20 (71) 17 (65)
    Adequate targeted therapy (n=52) 23 (87) 21 (88)
    Early oral Ciprofloxacin therapy (n=50) 1 0
    Late Ciprofloxacin therapy (n=49) 8 (30) 1  
 
 
Table 7: Comparison of antimicrobial resistance and antimicrobial exposure in the primary and 
first relapse BSI episodes 
 
Antibiotic
Antibiotic resistance in 
first BSI episode (n = 40)  
Antibiotic resistance in 
second BSI episode 
(n= 39)
Univariate 
Analysis 
Ticarcillin-clavulanate 5 (13%) 12 (31%)
Piperacillin-tazobactam 3/34 (9%) 5/28 ( 18%)
Ceftazidime 2 (5%) 3 (8%)
Cefepime 1 (3%) 4 (10%)
Meropenem 1 (3%) 3 (8%)
Any anti-pseudomonal beta-lactam 7 (18%) 13 (33%) p = 0.11
Treatment with any anti- 
pseudomonal beta-lactam in 30 
days prior to BSI episode
7/35(20%) 15/38 (39%) p = 0.04
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Discussion  
This multicentre retrospective cohort study characterised recurrent P. aeruginosa BSI.  A primary 
BSI relapse occurred in 9% of the cohort that survived to seven days post the primary BSI.  Of the 
35 patients that survived to 7 days post the first episode of BSI relapse, 14% of these patients went 
on to have a second episode of BSI relapse over the three year time period studied.  The BSI’s were 
predominantly hospital acquired and the most common source was a line associated infection.  The 
time to onset of the first episode of BSI relapse was highly variable.  Statistically significant 
variables associated with BSI recurrence were the presence of a hematological malignancy or 
having had corticosteroid therapy in the preceding 30 days.  The rate of mortality at 28 days post 
BSI was higher the greater the number of relapsing BSI episodes.   
Mylotte et al prospectively studied recurrent Gram-negative bacteraemia at a single centre.  
Recurrent Gram-negative BSI occurred in 9.8% of the cohort. There were 13 (17.5%) secondary 
episodes of Gram-negative infections caused by P. aeruginosa in the study [159].  More recently, 
Al-Hasan et al looked retrospectively at recurrent Gram-negative BSI in a population based study.  
P. aeruginosa accounted for 7% of the BSI’s.  They found a cumulative incidence rate of recurrence 
of all Gram-negative infections after 1, 5 and 10 years of the initial episode was 5.5%, 9.2% and 
14.6% respectively [160].  In both studies, the primary and relapsing BSI did not have to be caused 
by the same Gram-negative bacteria.  In our study, a first BSI relapse occurred in 9% of the cohort 
that survived to seven days post the primary BSI.  Of those patients that survived to 7 days post the 
first BSI relapse, there was a slightly higher rate of relapse, with 14% of this group having a further 
BSI.  
Corticosteroid therapy in the preceding 30 days and a hematological comorbidity placed an 
individual at risk for recurrent BSI on multivariate analysis. The occurrence of primary P. 
aeruginosa BSI infections in the haematology population is well described [161-163]. High rates of 
corticosteroid use were also described in the P. aeruginosa primary BSI cohort described by Joo et 
al [10].  Thus these two variables place an individual at risk for not only a primary BSI but also for 
its recurrence.  Although a vascular catheter source was the most common source in the first relapse 
of BSI, it was not significantly associated with recurrent infection.  This is in contrast to the 
recurrent all-cause Gram-negative bacteraemia study by Wendt et al [164]. This may reflect a 
practice of appropriate line removal in the setting of a primary P. aeruginosa BSI.  Neutropenia has 
been found to be a risk factor for primary BSI in a number of patient groups including those 
receiving chemotherapy and those patients with compromised bone marrow function [165].  In our 
cohort neutropenia was also not found to be significantly associated with patients that went on to 
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get a recurrent BSI. We did not find the adequacy of empirical or targeted antibiotic therapy to be 
significantly different between those patients that did and did not go on to have a recurrent BSI.   
Haki et al looked at antimicrobial susceptibility data that was available for 8 of the 10 cases of P. 
aeruginosa BSI recurrence from their stem cell transplantation cohort.  In 3 cases increasing 
antimicrobial resistance was seen [158].    Although we saw increased rates of resistance in the first 
relapse BSI patient group, this did not reach statistical significance.  Bhat et al showed that in their 
retrospective cohort of ICU patients with a P. aeruginosa isolate that was resistant to piperacillin-
tazobactam or cefepime, that the patient was more likely to have received these antibiotics in the 
month prior to the P. aeruginosa infection or to have had a Gram-negative bacillus resistant to these 
antibiotics isolated in the month prior to the P. aeruginosa infection [166].  We found that the group 
of primary BSI relapse patients was significantly more likely to have received anti-pseudomonal 
beta-lactams in the preceding 30 days. The small number of BSI episodes in our study may be the 
reason why we were not able to show significantly increased rates of resistance in the relapsing BSI 
episodes in light of this exposure.  Knowledge of recent antibiotic therapy received by a patient 
would seem important in choosing appropriate empirical therapy for the patient with the relapsing 
BSI.  
Al-Hasan et al in their recurrent Gram-negative BSI study found that mortality rates of  first and 
second Gram-negative BSI episodes were 10% and 11.3% [160]. Our study found that as the 
number of recurrent BSI’s increased the rate of patient death  at 28 days post the recurrent BSI also 
increased.  Supporting our finding, Hakki et al found that in their hematopoietic stem cell 
transplantation population, infection attributable mortality after the primary BSI was 35.8% and 
after BSI recurrence was 60% [158]. 
The limitations of this study are that it is retrospective and may have hidden biases.  In addition 
recurrent P. aeruginosa BSI is uncommon and thus the study had limited power.  It would have 
been ideal to obtain data on vascular catheter retention rates however this was poorly documented 
in patient notes.  Finally molecular typing of the isolates discussed would have allowed further 
insights into BSI recurrence.   
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Conclusion 
 
In conclusion this multicentre retrospective cohort study found that a recurrent P. aeruginosa BSI is 
uncommon.  Recurrence is significantly associated with a hematological co-morbidity and 
corticosteroid use in the preceding 30 days.  Those patients that survive a first BSI relapse of P. 
aeruginosa have an even higher risk of a further relapse of infection.  Recurrence is associated with 
increased mortality when compared to the primary BSI episode.  Knowledge of a patient’s prior 
antibiotic therapy may be useful in ensuring an active antibiotic against the BSI in an episode of 
BSI relapse.  
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3.3 Chapter Summary  
This chapter addresses the epidemiology and outcome of the little studied cohorts of community 
acquired and also relapsing P. aeruginosa BSI.  The research presented on community acquired P. 
aeruginosa BSI was the first to describe, in detail, the characteristics of the patients that have a 
community acquired acquisition of a P. aeruginosa BSI.   The CAI cohort could be divided into ten 
patient groups based on epidemiology and suspected clinical source of infection [19]. Improvement 
in identification of these patients at presentation will only be achieved by taking blood cultures and 
source sampling in the febrile patient.  This work also found that the distinct separation between 
HCAI and CAI for all-cause BSI’s was not found to apply to P. aeruginosa BSI’s. CAI was not 
found to have a better outcome at 28 days than HCAI, nor reduced length of stay.  The clinician 
should not be falsely reassured by community acquired acquisition of this infection [19].  
The focus of this chapter then changed to the description of the epidemiology of relapsing P. 
aeruginosa BSI.  This cohort has not been previously described in the literature.  Relapsing P. 
aeruginosa BSI was found to be uncommon [20].  Those patients that survived a primary BSI 
relapse of P. aeruginosa, were found to have an even higher risk of a further relapse of P. 
aeruginosa BSI.  Relapse was found to be significantly associated with a hematological co-
morbidity and corticosteroid use in the preceding 30 days.  A relapsing BSI episode was found to be 
associated with increased rate of mortality when compared to the primary BSI episode [20].  This is 
important epidemiologic knowledge for the clinician managing this infection.  
This work led to further questions regarding the molecular epidemiology of relapsing BSI.  
Specifically, are we infected with the same or a different genotype of P. aeruginosa when a BSI 
relapse occurs?  Does this depend on the source of relapsing infection? Is this time dependent?  
Chapter 4 goes on to explore the molecular epidemiology of relapsing P. aeruginosa BSI through 
the utilisation of iPLEX MassARRAY MALDI-TOF MS genotyping and DiversiLab genotyping.   
Further molecular epidemiology is presented in the second half of chapter 4 that focuses upon all 
the P. aeruginosa BSI isolates at a single institution and how they are related.  At this broader level, 
how does the interplay between environmental strains, those infecting or colonising the human host, 
local selection pressures and antibiotic resistance combine to effect the BSI clonal types in the 
hospital setting?  Are there only certain clonal types that are successful in causing a BSI?  Are we 
seeing the rise of predominant clones, reflected in the literature on antibiotic resistant isolates that 
are more successful in acquiring antibiotic resistance genes?  This work is relevant to infection 
control strategies and potential prevention of infection in the patient at risk for this BSI.   
60 
 
Chapter 4:  The molecular epidemiology of P. aeruginosa blood stream infection  
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Abstract 
 
Introduction 
P. aeruginosa isolate typing in the setting of recurrent P. aeruginosa BSI has not been studied. This 
study aimed to further characterise the genotypic relationship between the BSI isolates in this 
setting. 
 
Methods 
Patients with a primary and recurrent P. aeruginosa BSI were identified retrospectively from the 1st 
of January 2008 to the 1st of January 2013 from 5 different laboratories. Isolates were genotyped by 
iPLEX MassARRAY MALDI-TOF MS genotyping. If a clonal MLST type was found, DiversiLab 
genotyping was subsequently performed.  Epidemiological, clinical and microbiological data was 
obtained on the BSI episodes.   
 
Results 
It was found that a recurrent BSI from P. aeruginosa was more commonly from a genotypically 
related strain of P. aeruginosa.  Relapse due to a genotypically related bacterial isolate occurred 
earlier in time than a relapsing infection from an unrelated bacterial isolate (median time 26 versus 
91 days). Line related infections were found to be the most common source of suspected BSI.  
Almost half the BSI episodes were associated with neutropenia.  Development of meropenem 
resistance was seen in two relapsing BSI episodes.  
 
Conclusion 
In summary bacterial isolates giving rise to recurrent BSI in the setting of P. aeruginosa BSI are 
more likely to be genetically related, particularly if relapse occurs soon after the primary BSI 
episode.  Gut translocation may be another important source found in the setting of neutropenia. 
Antibiotic pressure from the treatment of a previous P. aeruginosa BSI episode may drive the 
subsequent development of antibiotic resistance in the recurrent BSI isolate.   
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Introduction 
Recurrent P. aeruginosa BSI’s have been reported in 6% of hospitalised patients with a primary P. 
aeruginosa BSI [20]. A haematological co-morbidity or having received steroids in the preceding 
30 days, have been found as risk factors for relapse [20]. Other high risk populations for relapse 
have been previously identified and consist of  liver transplantation recipients, hematopoietic stem 
cell transplant recipients and  acquired immunodeficiency syndrome (AIDS) patients [156-158].  In 
these cohorts rates of BSI recurrence of up 33% have been described [156-158].  Increased rates of 
patient mortality are seen in the setting of BSI relapse in comparison to the primary BSI episode 
[20]. 
The literature on relapsing Gram-negative BSI has focused on E. coli.  P. aeruginosa isolate typing 
in the setting of a relapsing P. aeruginosa BSI has not been studied.  It is not clear if subsequent 
infection is from the same or a different genotype of P. aeruginosa.  This study aimed to further 
characterise the genotypic relationship between the primary and relapsing P. aeruginosa bacterial 
isolates in the setting of a P. aeruginosa BSI.   
 
Methods 
 
Study population, case definitions and clinical data 
P. aeruginosa BSI isolates from patients who had blood cultures collected over a 5-year period (1st 
of January 2008 to the 1st of January 2013) were retrospectively identified from five public or 
private diagnostic pathology laboratories that service eight tertiary care hospitals and one secondary 
care hospital in metropolitan Brisbane, Australia.  These hospitals provide specialised and broad 
medical, surgical and intensive care for an urban population of 2.24 million.  Time periods of 
storage of BSI isolates varied between the laboratories.   
All isolates that had been stored by the laboratories were included in the initial analyses, with BSI 
episodes among individual patients defined as the 14 day period after the collection of the sentinel 
positive blood culture [21].  A relapsing BSI episode was defined as a subsequent P. aeruginosa 
positive blood culture occurring within the study period and outside of the preceding BSI episode.  
Patients with a relapsing BSI episode or episodes for which both of the BSI isolates were stored 
were included in the study. Patient data, including name, age, gender, date of birth and hospital of 
admission, was collected and correlated across the various pathology providers to ensure that cases 
of recurrent infection were not overlooked. The source of the initial BSI was determined by the 
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treating clinician at the time of notification of the positive blood culture. Permission to undertake 
the study was obtained from all laboratories involved. 
 
P. aeruginosa culture, identification and susceptibility testing 
Blood cultures, isolate identification and susceptibility testing was undertaken as previously 
described [21].   Briefly, each blood culture was incubated using the BD BACTECTM  blood culture 
system (BD, North Ryde, Australia) with an incubation period of up to five days. The system used 
depending on the particular laboratory.  Bacterial identification and susceptibility testing was 
achieved using the VITEK 2 system (bioMérieux Australia Pty Ltd). Annual CLSI breakpoints were 
used to define susceptibility or resistance to the antimicrobial agents tested [31].   From January 
2012 in one pathology service and July 2012 in another, antibiotic breakpoint references were 
changed to the EUCAST guidelines [32].  A standardised definition for multidrug resistant (MDR) 
bacteria was applied [30].  Confirmed P. aeruginosa isolates were stored at -800C using the Protect 
Microorganism Preservation System (Thermo Fisher Scientific Australia Pty Ltd, Thebarton, 
Australia) until transportation to a research laboratory. Upon receipt each isolate was resuscitated 
from -800C storage on Mueller-Hinton agar at 370C for 24 hours. 
 
P. aeruginosa iPLEX MassARRAY MALDI-TOF MS genotyping 
All of the P. aeruginosa isolates from patients with recurrent BSI episodes underwent genotyping 
with a single nucleotide polymorphism (SNP) based assay as outlined previously [21].  Briefly, heat 
denatured DNA preparations from each isolate were analysed using an iPLEX20SNP assay based 
on the Sequenom iPLEX MassARRAY matrix-assisted laser desorption ionisation with time of 
flight mass spectrometry (MALDI-TOF MS) platform. The iPLEX20SNP assay, comprising 20 
informative multilocus sequence typing (MLST) housekeeping gene SNPs, is capable of 
distinguishing most MLST sequence types (STs) either individually or as belonging to closely 
related single- or double-locus variant groups [167]. ST assignment of the 20-SNP profiles 
generated in the current study were performed by utilisation of the MLST database as described 
previously [167]. Twenty-SNP profiles which did not match with any of the listed 20-SNP profiles 
(i.e. an MLST type could not be assigned) were assigned as novel genotypes. If an isolate had a 20-
SNP profile with a singular non-typeable allele and a historical isolate was available with an 
otherwise identical 20-SNP profile, the former isolate was assigned to the same sequence type.   
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DiversiLab genotyping 
The DiversiLab automated rapid strain typing platform (bioMérieux Australia Pty Ltd) was used to 
assess the genotypic relationships between study isolates showing indistinguishable 20-SNP 
profiles. Genomic DNA was extracted using the MO BIO Ultraclean Microbial DNA isolation kit 
(MO BIO Laboratories Inc., Carlsbad, USA, MB-12224-250) as per the manufacturer’s instructions 
and repetitive element palindromic PCR (rep-PCR) was performed with the DiversiLab 
Pseudomonas kit using the previously outlined primer mix and PCR conditions [21].  Genetic 
relatedness was assessed using DiversiLab software version 3.6 (bioMérieux Australia Pty Ltd) 
with isolates showing fingerprints related by ≥95% were allocated to the same rep-PCR type. 
 
Definitions of genetic relatedness  
If a patient’s BSI isolates were assigned to the same 20-SNP profile that corresponded to a single 
ST, the BSI isolates were considered related.  Likewise, isolates cultured from an individual and 
allocated to the same novel 20-SNP genotype were considered related. For BSI isolates in which the 
20-SNP profiles corresponded to ≥2 STs, genetic relatedness was confirmed provided the isolates 
were also allocated to the same DiversiLab rep-PCR type.  
 
Statistics 
An unpaired Mann-Whitney test was utilised to compare continuous variables.  GraphPad Prism 6 
for Windows was used to perform calculations.   
 
Results     
        
P. aeruginosa BSI episodes 
Over the study period there were a total of 942 BSI isolates of P. aeruginosa identified that had 
been stored by the laboratories. Twenty-eight patients experienced one or more relapsing BSI 
episodes. Twenty five patients experienced one BSI relapse and three subjects experienced two 
relapsing episodes. The BSI episodes originated from nine different healthcare settings. Apart from 
one individual, the primary and secondary BSI episodes arose within the same healthcare setting. 
Community-acquired acquisition was not seen.  Further comments will relate to the first BSI 
episode and the primary relapse episode only for each patient (56 bacterial isolates).   
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Antimicrobial Susceptibility 
Fifty-six (100%) of the P. aeruginosa BSI isolates showed susceptibility to piperacillin-tazobactam. 
Only 4 isolates (7%) from 3 different patients showed evidence of meropenem resistance. In two 
patients the relapsing BSI episode isolate showed development of resistance to meropenem. 
Overall, only two isolates (4%) from a single patient exhibited a MDR phenotype that did not 
include resistance to meropenem.  
 
Genetic diversity of the P. aeruginosa Blood Stream Infection 
Details of the iPLEX20SNP and DiversiLab genotyping results of the primary and recurrent BSI 
isolates are presented in Table 8. Fourteen patients (50%) experienced recurrent infection with an 
isogenic (or related) strain of P. aeruginosa. In contrast, nine (32%) patients showed reinfection 
with an unrelated strain, while due to limitations in the genotyping strategy, the genetic relationship 
between the initial and subsequent P. aeruginosa isolates among five (18%) patients could not be 
determined.  
 
Source of the Blood Stream Infection  
A suspected source of infection was identified for 46 (82%) of the 56 P. aeruginosa isolates arising 
from the primary and secondary cases of BSI (Table 8). Of these, line-related infections were by far 
the most common source of infection having been implicated in 35 (76%) of the 46 P. aeruginosa 
positive blood cultures. Urinary (5 isolates), skin/soft tissue (3 isolates), abdominal (i.e. 
diverticulitis; 1 isolate) and cardiovascular (i.e. endocarditis; 2 isolates) sources were also 
identified.  
Overall, there were 17 subjects in whom a suspected source of infection was identified for the 
primary and secondary BSI with both isolates providing genotyping results. Eleven of these 
subjects experienced relapsing line-related infections with six patients showing a related P. 
aeruginosa strain in the two positive blood cultures. Relapsing BSI arising from the urinary tract 
and skin/soft tissue sources were also observed in two subjects (Subjects C and H).  In both cases 
this involved unrelated genotypes. Of the four subjects in whom there were differing sources of 
infection in the first and relapsing BSI episodes, an isogenic strain was identified in three cases 
(Subjects O, S and AA), while unrelated genotypes causing the BSI’s were observed in Subject E. 
This is summarised in Table 9.  
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Neutropenia at the time of P. aeruginosa BSI 
Blood cell count parameters were also available for 50/56 (89%) BSI episodes and showed that in 
21 (42%) instances the subjects were neutropenic at the time of blood culture collection.  
 
Time to relapse of BSI 
The median time to a primary BSI relapse was 49 days (interquartile [IQR] range: 26-101 days). 
For the 14 patients showing relapsing BSI’s with an isogenic P. aeruginosa strain the median time 
to recurrence was 26 days (IQR: 21-48 days). Conversely, if the primary recurrent BSI involved an 
unrelated P. aeruginosa strain (n=9 patients) the median time to relapse of BSI was 91 days (IQR: 
70-176 days; P=0.013). The three subjects (i.e. G, J, T) who experienced a second relapse BSI had 
P. aeruginosa cultured from their blood at 70, 322 and 56 days after the primary BSI recurrence, 
respectively. 
 
 
Table 8: Infection source, genotypic relationships and time to recurrence of the P. aeruginosa 
isolates cultured from the 28 study subjects showing relapsing blood stream infection  
 
 
Footnote 
Abbreviations: 20-SNP, Sequenom iPLEX 20-single nucleotide polymorphism assay genotype; ST, multilocus 
sequence type; rep-PCR, DiversiLab repetitive element palindromic PCR genotype; NT, non-typeable. 
a Line, line-related BSI; Skin/ST, skin or soft tissue focus of BSI; Urinary, BSI arising from a urinary tract infection; 
Unknown, a source of infection could not be identified; Cardiovas., BSI arising from endocarditis; Abdominal, BSI 
arising from diverticulitis 
b R, related genotypes; U, unrelated genotypes; I, indeterminant genotypic relationship 
c Subject G experienced two relapsing episodes of P. aeruginosa BSI. The second episode involved a line related 
infection comprising 20-SNP type CGTCGGCTCCTCCCCGGGCG (Predicted ST: 910, 1689; rep-PCR type: 13) at 70 
days after the primary relapse BSI. 
d Subject J experienced two relapsing episodes of P. aeruginosa BSI. The second episode involved a line related 
infection comprising 20-SNP type CGCAAGCTACCTCCTGGGTA (Predicted ST: NT) at 322 days after the primary 
relapse BSI. 
e Subject T experienced two relapsing episodes of P. aeruginosa BSI. The second episode involved a unknown source 
of BSI comprising 20-SNP type CGTCGGCTCTCCTTTGGGTA (Predicted ST: 147) at 56 days post the primary 
relapse BSI. 
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Table 9: Relationship of important clinical and laboratory variables to the genotypic 
relationships of the primary and relapsing P. aeruginosa BSI isolates  
 
 
Genetically Related 
Recurrent BSI Episodes 
(n=14)
Genetically Unrelated 
Recurrent BSI 
Episodes (n=9)
Indeterminate 
Relationship Between 
BSI Episodes (n=5)
Neutropenic during both episodes of bacteremia 4 2 2
Both episodes from the same source 7 6 3
Both episodes line related source of Infection 7 4 3
Development of meropenem resistance in the 
second episode 2 0 0
Median time between episodes (days) 26 91 150  
 
 
Discussion 
This study shows that recurrent P. aeruginosa BSI can occur from the same or different genotype, 
with recurrence from a genetically related strain occurring more frequently. Reinfection from a 
genetically related strain had a shorter median time to recurrence of 26 days, as compared to a 
median time of 91 days for BSI recurrence with an unrelated strain. The most common source for 
all the BSI episodes studied was line-related infection. Almost half of the BSI episodes were in the 
setting of neutropenia suggesting that gut translocation may be another potential source of the 
recurrent BSI.  
Although Gram-negative bacteria comprise a substantial component of normal human host 
microbiota, P. aeruginosa is infrequently reported [168]. The hospitalised host on the other hand, 
seems susceptible to colonisation with rates of up to 58% found in the intensive care unit (ICU) 
[169]. Host colonisation with one or multiple genotypes of P. aeruginosa has been described [170, 
171]. Colonisation may occur at many sites other than the bowel, including the perineum, throat, 
nose and axilla [168]. Colonisation may give rise to a secondary site of infection and subsequent 
bacteraemia [170, 172]. This study found that relapsing BSI from the same P. aeruginosa strain 
occurs earlier than with an unrelated strain. This may be reflective of the changing strain 
colonisation of the host with exposure to the environment which hosts multiple different strains of 
this organism [71].    
In our study 21 patients were neutropenic at the time of one of the BSI episodes, suggesting that 
endogenous translocation from the gastrointestinal tract may have been a potential source for some 
of these infections. Line-related infection causing both primary and relapsing BSI episodes was the 
most common cause of all BSI’s and the most common source when both BSI episodes were from 
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the same source of infection. The latter were more likely to be from genetically related than 
unrelated isolates. Unfortunately line removal data was not available to determine if line retention 
was responsible for the relapse of BSI. Intravascular devices were found to be the most common 
cause of recurrent all-cause Gram-negative bacteraemia by Wendt et al [164].   
Infective endocarditis was the cause of relapsing P. aeruginosa BSI in two patients. In one patient 
the genetic relationship of the BSI isolates was indeterminate. The source of the primary infection 
was also unknown. In the second patient the BSI isolates from the primary and recurrent episodes 
were found to be genetically related with the primary BSI thought to line-related. In this latter 
infection the isolate was meropenem resistant in the relapsing episode. The antibiotic therapy this 
patient received is unknown.  It would seem likely that antibiotic selection pressure drove the 
development of antibiotic resistance in this patient. There was one other patient in whom a relapsing 
infection with an isolate that had become meropenem resistant, both the primary and relapsing BSI 
of a line related aetiology.   The patient’s recent antibiotic therapy was also unknown.   
The limitations of this study include that the number of recurrent P. aeruginosa BSI episodes 
studied is small. This is due to a combination of the rarity of relapse of this infection and that the 
retrospective identification of the isolates for the study depended on the laboratories having stored 
the isolates after routine isolate identification. Sampling bias may also be present due to the 
differing time periods the differing laboratories had stored isolates available for study. Also only 
limited clinical data was available on all of the patients studied.   
 
In summary relapsing P. aeruginosa BSI from the same genotype occurs earlier in time than a 
subsequent infection from an unrelated genotype. Development of meropenem resistance was seen 
in two relapsing BSI episodes.  Antibiotic pressure from the treatment of a previous P. aeruginosa 
BSI episode may drive the subsequent development of antibiotic resistance in the recurrent BSI 
episode.   
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4.2: The molecular epidemiology of P. aeruginosa blood stream infection isolates 
in a non-outbreak setting 
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Abstract 
 
Introduction 
The molecular epidemiology of P. aeruginosa BSI  isolates has received limited attention.  This 
study aims to characterise the molecular relationship of P. aeruginosa bloodstream infection 
isolates in the non-outbreak setting at a single tertiary healthcare facility.   
 
Methods 
P. aeruginosa BSI isolates from patients who were admitted to the Royal Brisbane and Women’s 
Hospital over a 13 month period from November 2009 were identified retrospectively from the 
Pathology Queensland Clinical and Scientific Information System. The isolates were typed by 
iPLEX MassARRAY MALDI-TOF MS genotyping. The DiversiLab automated rapid strain typing 
platform (bioMérieux Australia Pty Ltd) was used to assess the genotypic relationships between 
study isolates that showed indistinguishable iPLEX20SNP profiles.  Clinical data was also collected 
retrospectively from patient notes.  
 
Results 
Fifty three P. aeruginosa BSI episodes were available for study.  Thirty five different clones or 
clonal complexes were identified by iPLEX MassARRAY MALDI-TOF MS genotyping.  Seventeen 
BSI isolates with indistinguishable iPLEX20SNP profiles underwent further  DiversiLab  
genotyping and were found to belong to a further 13 different  genotypes.  There was no 
relationship between clonality and acquisition type, source of infection or length of stay in the 
setting of HAI.   
 
Conclusion 
The non-clonal population structure suggests that there is ongoing environmental exposure of 
inpatients to P. aeruginosa.  In clinical areas dealing with the at risk patient, routine attention to 
mechanism of environmental colonisation is important and should be addressed even in the non-
outbreak setting.   
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Introduction 
P. aeruginosa is an important opportunistic pathogen that is capable of causing life threatening 
illness, including BSI in the vulnerable host.  The majority of infections are HAI.  However both 
HCAI and CAI have also been described.   Respiratory, urinary tract, soft tissue and central line 
associated infections have all been described as important sources of BSI.  The mortality from this 
BSI has been described up to 42%, depending on the population studied [22].   
Molecular typing of P. aeruginosa has been predominantly studied in three distinct settings: cystic 
fibrosis (CF), during nosocomial outbreaks and when comparing environmental and a range of 
clinical isolates, sampled from different geographical locations.   In the latter setting there appears 
to be a limited association between genotype and the ecological setting.  Also described as a non-
clonal epidemic population structure [68, 71].   Most CF outbreak and nosocomial outbreak strains 
represent a random sample of the broader P. aeruginosa population diversity punctuated by highly 
successful clones or clonal complexes [68, 71, 173, 174].  A recent study in the nosocomial setting 
showed for the first time successful international spread of a ST235 clonal type with a VIM-2 
metallo beta-lactamase in Russia, Belarus and Kazakhstan [79].   
To date, the molecular epidemiology of P. aeruginosa BSI isolates has received little attention.  In 
this study we sought to characterise the molecular relationships between P. aeruginosa BSI isolates 
cultured in a non-outbreak setting at a large tertiary healthcare facility.  
 
Methods 
 
Study population 
P. aeruginosa BSI isolates from patients who were admitted to the Royal Brisbane and Women’s 
Hospital, Queensland, Australia from the first of November 2009 to the 30th of November 2010 
were retrospectively identified from the Pathology Queensland Clinical and Scientific Information 
System (AUSLAB).   Each BSI episode was defined as the 14 day period after the collection date of 
the sentinel positive blood culture.  Permission to carry out the study was obtained from Pathology 
Queensland and also the Royal Brisbane and Women’s Hospital Ethics Committee.   
 
P. aeruginosa culture, identification and susceptibility testing 
Blood cultures were undertaken by a routine diagnostic laboratory using the BD BACTEC™ blood 
culture system (BD, North Ryde, Australia) with an incubation period of up to 5 days. Upon 
detection each culture positive blood sample was inoculated onto blood, chocolate and MacConkey 
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agars and then incubated at 350C in either 5% CO2 or aerobic conditions. After overnight incubation 
the P. aeruginosa isolates were identified by a positive cytochrome c oxidase test and the VITEK 2 
system (bioMérieux Australia Pty Ltd, Baulkham Hills, Australia). Sentinel isolates from each BSI 
episode were stored at -800C using the Protect Microorganism Preservation System (Thermo Fisher 
Scientific Australia Pty Ltd, Thebarton, Australia). For the purposes of this study each isolate was 
resuscitated from -800C storage on Mueller-Hinton agar plates at 370C for 24 hours.  Disc diffusion 
susceptibility testing to aztreonam, ceftazidime, ciprofloxacin, gentamicin, piperacillin-tazobactam 
and meropenem was performed on all isolates according to EUCAST guidelines and interpretative 
breakpoints [32, 175]. A standardised definition for multidrug resistant (MDR) bacteria was used 
[30].   
 
P. aeruginosa iPLEX MassARRAY MALDI-TOF MS genotyping 
Heat denatured suspensions of each strain were prepared by heating 1mL of a 1.0 McFarland 
suspension in sterile H2O at 100
0C for 10 minutes. Samples were then vortexed and centrifuged at 
3000 rpm for 5 minutes with the supernatants thereafter used for genotyping. Genotyping was 
undertaken on all isolates using a single nucleotide polymorphism (SNP) based typing assay (i.e. 
iPLEX20SNP assay) based on the Sequenom iPLEX MassARRAY matrix-assisted laser desorption 
ionisation with time of flight mass spectrometry (MALDI-TOF MS) platform as described 
previously [167]. Briefly, the iPLEX20SNP assay comprises 20 informative SNPs characterised 
from multilocus sequence typing (MLST) housekeeping genes. Previous in silico analyses have 
demonstrated that compared to MLST the iPLEX20SNP assay shows a high discriminatory power 
and is capable of distinguishing most MLST sequence types (STs) either individually or as 
belonging to closely related single- or double-locus variant groups [167]. Sequence type assignment 
of the 20-SNP profiles generated in the current study were performed by utilisation of the MLST 
database as described previously [167]. If a 20-SNP profile had not been previously described it 
was classified as a novel ST.   
 
DiversiLab genotyping 
The DiversiLab automated rapid strain typing platform (bioMérieux Australia Pty Ltd) was used to 
assess the genotypic relationships between study isolates that showed indistinguishable 
iPLEX20SNP profiles.  Genomic DNA was extracted using the MO BIO Ultraclean Microbial 
DNA isolation kit (MO BIO Laboratories, Inc., Carlsbad, USA, MB-12224-250) as per the 
manufacturer’s instructions.  Repetitive element palindromic PCR (rep-PCR) was performed with 
the DiversiLab Pseudomonas kit using primer mix O.  The PCR conditions were initial denaturation 
at 94oC for 2 minutes, annealing temperature at 50oC for 30 seconds and extension at 70oC for 30 
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seconds, and followed by a final extension at 70oC for 3 minutes.  Genetic relatedness was assessed 
using DiversiLab software version 3.6 (bioMérieux Australia Pty Ltd) .  Isolates producing 
fingerprints related by ≥95% were allocated to the same rep-PCR type.  
 
Clinical data and Case definitions 
Detailed clinical data including age, gender, clinically suspected source of the BSI, admission date, 
discharge date and admitting speciality were retrospectively collected from the patients case notes.   
Each BSI was classified into acquisition type based on modified Centers for Disease Control and 
Prevention definitions.  A HAI being defined as a positive blood culture obtained from a patient 
after 48 hours of hospitalisation or within 48 hours of discharge.  A HCAI being defined as a 
positive culture obtained from a patient at the time of hospital admission or within 48 hours of 
admission if the BSI fulfilled any of the following criteria: 1. A complication of an indwelling 
medical device; 2. Occurs within 30 days of a surgical procedure where the BSI is related to a SSI; 
3. An invasive instrumentation or incision related to a BSI was performed within 48 hours before 
the onset of infection.   If the timing of onset was longer than 48 hours there must be compelling 
evidence that the infection was related to an invasive device or procedure; or 4. Received therapy 
with temporary intravenous access in the 48 hours before the onset of infection.  If the timing of 
onset was longer than 48 hours there must be compelling evidence that the infection was related to 
the invasive device or procedure; 5. Associated with neutropenia (< 0.5 x 109/L) contributed to by 
cytotoxic therapy; 6. The patient resided in a nursing home.   A CAI being defined as a positive 
culture obtained at the time of hospital admission or within the first 48 hours after admission which 
does not fit the criteria for a HCAI [136, 137].   The suspected source of the BSI was classified 
according to clinical judgement at the time of the BSI.  Patient bed movement data for patient 
admissions to the health-care facility prior to, during and after the admission including the BSI 
episode studied, were obtained from the hospital based corporate information system (HBCIS) 
database.   
 
Results 
Over the 13 month period we identified a total of 72 episodes of P. aeruginosa BSI from 67 patients 
admitted to the Royal Brisbane and Women’s Hospital.  Fifty-three (74%) of the 72 BSI isolates 
were available for further testing.   The 53 BSI isolates studied represented 48 different patients 
(Table 10).  Four of the patients had a further recurrent BSI episode.  One patient had 2 recurrent 
BSI episodes.  Thirty-five of the P. aeruginosa BSI isolates were from a HAI, 12 from a HCAI, 4 
from CAI and 2 were an unknown acquisition type. The BSI isolates were highly susceptible to the 
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antibiotics tested with only 1 MDR isolate.  Excluding the recurrent infection episodes the majority 
of patients with a BSI were male (65%) and the median age was 60 (range: 20-82) years.  The most 
frequently suspected clinical sources of all BSI’s were central line-associated infections (19 
episodes), UTI’s (13 episodes) and pneumonia (8 episodes). While surgical site, skin or soft tissue 
and port exit site infections each accounted for only one BSI episode.  Haematology was the 
predominant speciality responsible for patient care.  In regards to HAI episodes, excluding the 
episodes involving hospital readmission, the range of time from admission to collection of the 
sentinel blood culture containing the P. aeruginosa isolate was 3 to 114 days, with a median of 16 
days. 
The iPLEX20SNP genotyping of the 53 BSI isolates revealed 35 different 20-SNP types. Five 
isolates were deemed untypeable.  When the 35 20-SNP profiles (48 isolates) were used to predict a 
MLST type, 29/35 matched profiles obtained from the MLST website to provide a predicted MLST 
type or types. Six 20-SNP profiles (6 isolates) did not match with any of the listed 20-SNP profiles 
meaning that a MLST type could not be assigned.  Twenty eight (80%) of the 35 20-SNP profiles 
pertained to individual isolates. The remaining seven 20-SNP profiles had greater than one isolate 
assigned to them.  Of these seven 20-SNP-profiles the predicted MSLT types represented 6 
different clonal clusters and 1 singular clone.  A number of the MLST types identified have been 
previously described in the greater Brisbane environment or in clinical strains [71].  The strain types 
associated with drug resistance in the hospital setting ST 111, ST 175 and ST 235 [75, 76, 78, 79, 
176-181] were not seen in the current evaluation.   
The most common iPLEX20SNP genotype was 3, which was detected in BSI isolates from 4 
patients.  iPLEX20SNP genotypes  5 and 7 were detected in BSI isolates from 3 patients each, 
while genotypes 6, 8, 10 and 24 were detected in BSI isolates from 2 patients each.  iPLEXSNP  
genotype 5 represented a single MLST type 222. This is in contrast to the other 5 genotypes 
described that represented MLST clonal clusters.  The 17 BSI isolates that were assigned to these 5 
iPLEXSNP genotypes underwent further DiversiLab genotyping (Figure 2).  These isolates 
belonged to 15 different patients.  Thirteen different DiversiLab genotypes were identified.  In 
detail there was no genetic variation found on DiversiLab typing among the two isolates belonging 
to the assigned iPLEXSNP genotype 10.  Three of the four isolates assigned to the iPLEXSNP 
genotype 3 also showed an indistinguishable rep-PCR type.  Two of the 3 isolates assigned to the 
iPLEXSNP genotype 6 were assigned also to the same DiversiLab genotype.  The 2 isolates 
assigned to the iPLEXSNP genotype 8 were assigned to different DiversiLab genotypes.  Each of 
the 4 isolates assigned to the iPLEXSNP genotype 7 were assigned to a different DiversiLab 
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genotype.  The two isolates assigned to the iPLEXSNP genotype 24 were assigned to different 
DiversiLab genotypes (Figure 2).   
Overall there was no relationship between the source of infection and clonality.  There was limited 
cross over between clone/cluster types and acquisition type.   Three of the HCAI isolates belonged 
to the same iPLEXSNP genotype 5 which represented a single MLST sequence type 222.   Each 
patient was managed by a different hospital team and there was no cross over of patient movement 
during the prior or respective BSI episode.  Of the 3 DiversiLab genotypes that involved more than 
1 BSI isolate, all involved a HAI acquisition type.   The two isolates assigned to DiversiLab 
genotpe A represented a CAI and a HAI BSI acquisition.  The 3 isolates assigned to DiversiLab 
genotype B involved both HCAI and HAI BSI acquisitions.  On review of patient movement data 
for these patients there was again no evidence of commonality of ward location at any time point 
during any relevant hospital admissions.    The two isolates assigned to DiversiLab genotype C 
represented a recurrent BSI in one patient.  There was no relationship between clonality and length 
of stay for HAI BSI isolates.   Overall there was no evidence of cross transmission of any the 
common clonal types seen by any of the typing methods, on review of patient movement data. 
 
Table 10: P. aeruginosa BSI iPLEX20SNP genotyping results and associated host characteristics 
 
 
Footnote:  Community acquired infection (CAI), healthcare acquired infection (HCAI), hospital acquired infection 
(HAI), line related infection (line), surgical site infection (SSI), urinary tract infection (UTI), Readmission Day 1 (R1). 
* Second isolate on patient within the series 
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Figure 2: DiversiLab genotyping results of BSI study isolates that showed indistinguishable 
iPLEX20SNP profiles 
 
 
 
Discussion 
This study found that there was a non-clonal population structure of the P. aeruginosa isolates 
causing BSI in a single tertiary institution when studied over a 13 month period. There was no 
association between acquisition type, origin of infection or the length of stay in the HAI group and 
the genotypes seen.  The isolates were highly susceptible and the strain types previously associated 
with drug resistance, ST 111, ST 175 and ST 235, were not seen.   There was not a singular 
successful clone causing invasive BSI but many successful clonal types.   The diversity of clonality 
of the BSI isolates seen most likely reflects environmental exposure of the vulnerable host.  
Molecular typing of a broader sample of clinical isolates in the hospital setting and appropriate 
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environmental sampling may help better understand hospital sources of exposure and appropriate 
infection control strategies.  
In the hospital setting epidemic clones of P. aeruginosa causing outbreaks of BSI infection are well 
described in the published literature.  Identified sources have included hospital staff in the setting of 
artificial fingernails, onychomycosis or intermittent otitis externa [182-184]. Other identified 
hospital sources have included contaminated tubing used for irrigation of burns patients, 
contaminated endoscopes and contaminated water basins [185-187].  Epidemic clonal transmission 
has also been described in the 
setting of both BSI and other sites of P. aeruginosa infection in the setting of carbapenem resistance 
conferred by MBL. The majority of isolates belong to a few successful clones such as ST 111, 
ST175 or ST235.  This has been seen worldwide [75, 76, 78, 79, 176-181].   
The molecular epidemiology of P. aeruginosa BSI in the non-outbreak setting has not been well 
described.   Pirnay et al, Kidd et al and Gomilla et al have looked at a limited number of BSI 
isolates in the setting of a broader sampling of clinical isolates [68, 71, 177].   In detail Pinay et al 
characterised 328 diverse and unrelated P. aeruginosa strains from both the clinical setting and 
external environment by MLST.  Clinical isolates were indistinguishable from environmental 
isolates. Interestingly the isolates were widespread in the environment without specific habitat 
selection [68]. This non-clonal population structure was also found by Kidd et al in their 
characterisation of environmental and range of clinical P. aeruginosa isolates in South-East 
Queensland [71].   
In our study focusing on BSI isolates, forty two different clones/clonal complexes were identified 
from the 53 isolates characterised.    The lack of genotypic relationship between the P. aeruginosa 
isolates studied suggests an environmental source of infection, with many successful clonal types 
causing invasive infection.   Also supporting an environmental origin is a lack of association with 
the clone/clonal complex and whether the infection was acquired in the hospital, healthcare 
associated or community setting.  In addition some of  the singleton clonal types have been 
previously described by Kidd et al in the Brisbane environmental setting:  266 and 870 from the 
Brisbane river and  222 from the water of a municipal pool [71].  There was no suggestion of cross 
transmission between the patients with hospital acquired BSI.   
In terms of the hospital environment, components of the tap (faucet) particularly the body, 
supporting metal collars and flow straighteners have been found to be reservoirs of P. aeruginosa 
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[188-190].  This has also been found for sinks, tubing used for local irrigation and shower heads 
[185, 189, 191].  Quick et al found that even in a new hospital, P. aeruginosa can become rapidly 
endemic in the hospital plumbing [189].  This group also showed that the water supply was the 
origin of the clones in their hospital [189].  Reuter et al studied the source of the P. aeruginosa 
patient colonisations and infections in their intensive care unit.  Their longitudinal sampling 
suggested that there was evidence of transmission from patients to the faucets resulting in 
colonisation.  Both short term and long term colonisation of differing genotypes was found [188]. In 
the United Kingdom (UK)  recently introduced  national guidelines have been put in place for 
routine water sampling in augmented care units with directed  interventions such as disinfection and 
replacement of high risk plumbing parts as required [189].  
It is also known that the greater the length of hospitalisation of a patient the greater the risk of 
colonisation with P. aeruginosa [191-193].   The majority of infections in this study were HAI.  
However colonisation of the host by P. aeruginosa prior to admission is a possible source of 
subsequent infection.  Lepelletier et al looked at patient gastrointestinal colonisation in 5 different 
wards at a French university hospital.  Newly admitted patients had a rectal swab as part of the 
study.   In the routine wards  the proportion of culture positive patients was 1.9 to 8.7% [193].  
Food may also be a source of colonisation in at risk patient.  Washed or unwashed vegetables and 
fruit may potentially be another mechanism of transmission to the at risk patient [168].  Wright et al 
identified P. aeruginosa from the vegetable salads served to patients at their hospital [194].  
It must be remembered that BSI are only one of many infections that P. aeruginosa causes.  We 
have not typed isolates from other infections over the time period studied nor isolates causing 
patient colonisation.  This would give us a more complete picture of the clonal types in this 
institution. We cannot exclude some cross transmission between patients being the source of 
colonisation and subsequent BSI.  However the diversity of clonal and cluster types we have seen 
would see suggest that environmental exposure is the main source of these isolates.   
In summary the P. aeruginosa BSI isolates studied over 13 months at a single institution were 
diverse in their clonal structure. There was evidence of many successful P. aeruginosa clonal types.  
As the majority of infections were HAI, this suggests that there is ongoing environmental exposure 
of inpatient to P. aeruginosa.  P. aeruginosa BSI is an infection with considerable morbidity and 
mortality.  This would suggest that in areas of the hospital dealing with the at risk patient, routine 
attention to mechanism of environmental colonisation is important and should be addressed even in 
the non-outbreak setting.   
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4.3: Chapter summary 
 
This chapter provides further insight into the molecular epidemiology of P. aeruginosa BSI.  In the 
setting of BSI the published literature focuses upon the epidemiology of outbreaks, particularly of 
resistant P aeruginosa BSI.  However in the clinical setting there are many new infections on a 
daily basis that are not part of an outbreak.  How these were related at a molecular level was not 
known.  The work in this thesis shows there was not a singular successful clone causing invasive 
BSI but many successful clonal types [21].   The diversity of clonality of the BSI isolates most 
likely reflects environmental exposure of the vulnerable host even in the inpatient setting.  This 
ongoing exposure is theoretically preventable and has possible infection control implications in the 
vulnerable patient. 
The molecular epidemiology in the setting of recurrent P. aeruginosa BSI has not been previously 
studied.  The literature on recurrent BSI has focused on Enterobacteriacaeae.  This chapter 
demonstrated that in a patient with a recurrent infection this was more likely to occur from the same 
genotype.  In addition infection from the same genotype was more likely to occur the closer in time 
the BSI episodes occurred. Line related infections and gut related translocations of bacteria are 
likely important sources of relapsing infection.  
So far we have looked at the clinical and molecular epidemiology of P. aeruginosa BSI.  Mortality 
associated with this BSI has been highlighted in the sections focusing on clinical epidemiology. The 
characteristics of the host have been focused upon.  The next chapter moves the discussion forward 
and focuses upon the bacterium, P. aeruginosa.  How does this organism contribute to mortality in 
the setting of a BSI?  The BSI isolates from five BSI episodes associated with rapid patient death, 
that were described in chapter two, are studied further.   
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Chapter 5:  Virulence characteristics of P. aeruginosa strains isolated in fatal 
cases of blood stream infection 
5.1:  Introduction 
 
Patient mortality in the setting of a P. aeruginosa BSI has been described in detail in chapter two. 
The epidemiological, clinical and microbiological factors of the host and the BSI isolate associated 
with death were studied in detail.  However, the virulence characteristics of the bacterium has not 
been fully investigated.  Pena et al performed a post hoc analysis of a published prospective 
multicentre cohort of P. aeruginosa BSI’s [114].  The multivariate analysis included 
epidemiological, clinical and microbiological characteristics potentially associated with mortality.   
However it was unique in that it also looked at the presence of the type three secretion system 
(TTSS) which is a known virulence mechanism of P. aeruginosa.  The presence of the TTSS was 
found to be independently associated with patient mortality [114]. There has been limited analysis 
in the literature of P. aeruginosa virulence genes in clinical isolates due to the routine technology 
previously available.  The detail of genome analysis provided by whole genome sequencing allows 
expansion of the research that has been performed. This chapter analyses five P. aeruginosa BSI 
isolates that were the cause of the BSI episode in five patients of the cohort described in chapter 
two. In each of the BSI episodes the patient experienced death within 48 hours of sentinel blood 
culture collection.  The aim of this chapter was to further explore the virulence characteristics of 
these P. aeruginosa BSI isolates.   
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5.2: P. aeruginosa blood stream infection isolates: A “full house” of virulence 
genes in the setting of early patient death  
Abstract 
 
Introduction 
We have recently characterised the epidemiology of P. aeruginosa BSI in a large retrospective 
multicentre cohort study [18].  Utilising corresponding patient BSI isolates we aimed to characterise 
the genotypic virulence profile of the P. aeruginosa isolates that were associated with rapid death in 
the non-neutropenic host.   
 
Methods 
Five P. aeruginosa BSI episodes were identified from a larger cohort of P. aeruginosa BSI  
episodes previously described  by McCarthy et al [18].  These episodes were in patients who were 
non-neutropenic and had experienced rapid death.  These isolates underwent Illumina whole 
genome sequencing and were de novo assembled using SPAdes  v3.8.1 .  Annotation was 
performed by the NCBI Prokaryotic Genome Annotation Pipeline. A comprehensive suite of 
virulence genes was determined by utilising the Pseudomonas Genome Database  
(http://www.pseudomonas.com/) [195].  For the HigB toxin, primer sequences were obtained and 
blasted to identify the gene product [116].  For a gene to be considered present searching required 
100% of the gene to be present in the BLAST output. For both the Exolysin (ExlA) protein and the 
ExoU protein the reads were mapped in CLC Genomics Workbench V7.5.1  to the exlA (allele 
PSPA7_RS22085 in PA7 genome) or exoU (PA14_51530  allele in the PA14 genome).  
 
Results 
There was extensive conservation of virulence genes studied across all five of the BSI isolates 
studied. Two of the isolates contained the exoU gene.  The higA and higB genes were detected in all 
isolates. The exlA gene was not detected in any of the isolates studied. 
 
Conclusion 
These findings may reflect that to cause both a BSI and rapid death that it is only the highly virulent 
P. aeruginosa isolate that succeeds.  Further phenotypic correlation is required.  
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Introduction 
 
With the utilisation of whole genome sequencing we have been able to gain greater understanding 
of the genome of P. aeruginosa.  It is a large genome of 6.3 MB, containing on average more than 
6175 genes [110].   The core genome represents on average 88% of the  genome [112].  In 
comparison to the conserved core genome, the regions of the accessory genome are heterogeneous 
and contain genes identified from other bacteria [111].  Valot et al found that approximately one 
third of virulence genes are found in the accessory genome, the rest sitting in the core genome 
[112].   
The virulence genes of P. aeruginosa, outside of the cystic fibrosis setting, have been studied in a 
limited fashion in such cohorts as burn infections, UTI’s and BSI’s [196-198].  More recently Pena 
et al studied a large cohort of patients with P. aeruginosa BSI [114].  They were able to show that 
the genotypic presence of exoU was significantly associated with early death.  This was found to be 
more significant than the traditional patient risk factors also studied [114].  Elsen et al have recently 
described a toxin that causes hyper virulence in P. aeruginosa called ExlA [199].  Study in the 
context of patient outcomes has not been studied thus far.   
We have recently characterised the epidemiology of P. aeruginosa BSI in a large retrospective 
multicentre cohort study [18].  Utilising corresponding patient BSI isolates we wished to 
characterise the virulence genes profile of the P. aeruginosa isolates that caused rapid death in the 
non-neutropenic host.   
 
Methods 
 
Study population 
P. aeruginosa BSI’s were studied retrospectively in a multicentre cohort study from the first of 
January 2008 to the first of January 2011 [18].   A BSI episode was identified as the 14 day time 
period from the date of the first positive blood culture.  Five hundred and ninety-five episodes of P. 
aeruginosa BSI were identified over the three year period.  After predefined exclusion criteria were 
applied, 388 monomicrobial non-recurrent BSI episodes from 388 patients were available for 
further analysis.  This has been described in detail elsewhere [18].   
At 48 hours post the collection of the sentinel blood culture 17 patients, representing 17 BSI 
episodes had died [18].  Of these patients, six were neutropenic within the 14 day period prior to the 
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BSI episode and were excluded from this virulence study.  In one patient their neutrophil count was 
not known and they were also excluded.  Of the remaining ten BSI episodes, five of the BSI isolates 
had been stored by the servicing laboratory and were available for further study.   
The five P. aeruginosa isolates studied caused BSI in a non-neutropenic patient who experienced 
death within 48 hours of collection of the blood culture from which the bacteria were identified.  
The host studied was not free of co-morbidities with two of the patients having metastatic small cell 
lung cancer and one patient having chronic lymphocytic leukaemia.  Two of the patients had 
received chemotherapy in the preceding 30 days and three patients recent corticosteroid therapy.  
The BSI episodes were monomicrobial, non-recurrent and phenotypically susceptible to all the 
antibiotics tested.  All BSI isolates originated from a lung source of infection.  In two BSI episodes 
the patients did not receive empirical therapy that would have adequately covered the infecting P. 
aeruginosa isolate.   
 
Microbiological Methods 
Blood cultures were undertaken by the routine diagnostic laboratories using the BD BACTEC™ 
(43003-1) blood culture system (BD, North Ryde, Australia) with an incubation period of up to five 
days. Upon detection each culture positive blood sample was inoculated onto blood, chocolate and 
MacConkey agars and then incubated at 350C in either 5% CO2 or aerobic conditions. After 
overnight incubation the P. aeruginosa isolates were identified by the VITEK 2 system (bioMérieux 
Australia Pty Ltd, Baulkham Hills, Australia). Confirmed P. aeruginosa isolates were stored at -
800C using the Protect Microorganism Preservation System (Thermo Fisher Scientific Australia Pty 
Ltd, Thebarton, Australia) until transportation to a research laboratory. Upon receipt each isolate 
was resuscitated from -800C storage on Mueller-Hinton agar at 370C for 24 hours.  Antimicrobial 
susceptibility testing was performed by a microdilution method on the VITEK 2 system. Clinical 
and Laboratory Standards Institute breakpoints were used to define susceptibility or resistance to 
aztreonam, ticarcillin-clavulanate, piperacillin-tazobactam, ceftazidime, cefepime, meropenem, 
ciprofloxacin and gentamicin [31].    
 
Whole Genome Sequencing and Analysis 
Paired end libraries of whole genomic DNA (QIA symphony DSP DNA Mini kit) of all 5 isolates 
were prepared by the Nextera library protocol and sequenced by Illumina HiSeq2000 or 
NextSeq500 (Illumina, San Diego, CA, USA). Sequences were trimmed in CLC Genomics 
Workbench. All sequences were de novo assembled using SPAdes v3.8.1. Annotation was 
performed by the NCBI Prokaryotic Genome Annotation Pipeline. The draft genomes were 
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4,654,913 to 6,618,287 bp long consisting of 112 to 400 contigs. (MWZF00000000.1 Total number 
of genes: 6520 , Coding Sequences (CDS) 6248, tRNA 50, non-coding RNA 4; MWZG00000000.2  
Total number of genes: 5197, CDSs 5143,  tRNA 47 and non-coding RNA 3; MWZH00000000.1  
Total number of genes: 5380 , CDSs 5168, tRNA 43, non-coding RNA 4; MWZI00000000.1 Total 
number of genes: 4563 , CDSs 4512,  tRNA 44 and non-coding RNA 4; MWWL00000000.1 Total 
number of genes: 6502 , CDSs 6440, tRNA 55, non-coding RNA 4).  Contigs of the draft genomes 
were submitted to the Centre for Genomic Epidemiology (http: //www.genomic epidemiology.org) 
to identify the resistance genes of each isolate with the database Resfinder 2.1 [200] . The sequence 
type (ST) of each isolate was also identified by the P. aeruginosa MLST database 1.7 [201].  A 
comprehensive suite of virulence genes was determined by utilising the Pseudomonas Genome 
Database  (http://www.pseudomonas.com/) [195].  For the HigB toxins, primer sequences were 
obtained and blasted to identify the gene product [116].  For a gene to be considered present 
searching required 100% of the gene to be present in the BLAST output. For both the Exolysin 
(ExlA) protein and the ExoU protein the reads were mapped in CLC Genomics Workbench V7.5.1 
 to the exlA (allele PSPA7_RS22085 in PA7 genome) or exoU (PA14_51530  allele in the PA14 
genome).   
 
Results 
 
The virulence gene profiles of the isolates were all unique and in two instances comprised novel 
genotypes on the PubMLST database.  The genotypic antibiotic resistance profiles of each isolate 
are also described in Table 11.  Phenotypically the isolates were all found to be susceptible to 
ceftazidime, cefepime, ticarcillin-clavulanate, piperacillin-tazobactam, meropenem, gentamicin and 
ciprofloxacin.  
The genotypic virulence profiles of the isolates were determined as per Table 12.  There was 
extensive conservation of virulence genes studied across all five of the BSI isolates. Two of the 
isolates contained the exoU gene.  The higA and higB genes were detected in all isolates. The exlA 
gene was not detected in any of the isolates studied. 
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Table 11: MLST and antibiotic resistance genotype of the five BSI isolates studied 
 
Isolate Number 1 2 3 4 5
MLST type ST-5690 St-309 St-898 Unknown ST Unknown ST
Antibiotic Resistance Genotype
Aminoglycosides 
(Kanamycin, Neomycin, 
Gentamicin, Paromycin) aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b aph(3')-2b
Meropenem blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50 blaOXA-50
Ceftazidime bla PA0 bla PA0 bla PA0 bla PA0 bla PA0
Chloramphenicol catB7 catB7 catB7 catB7 catB7
Fosfomycin fosA fosA fosA fosA fosA  
Foot note: Multilocus sequence type (ST) 
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Table 12: Genotypic virulence profile of the five BSI isolates studied 
 
Isolate Number 
System Virulence Factor Gene 1 2 3 4 5
Type 1 Secretion System Alkaline phosphatase aprF + + + + +
Heme acquistion protein hasAP + + + - +
Type 2 Secretion System Elastase lasB + + + + +
Protease Precursor lasA + + + + +
Non-hemolytic phospholipase C precursor pcLN + + + + +
Protease piv - - - - +
Lactonising lipase precursor lipA - - + + +
Lipase lipC + + + + +
Exotoxin A precursor toxA + + + - +
Low-molecular weight alkaline phosphatase lapA + - + + -
Metalloendopeptidase mep72 + + + + +
Type 3 Secretion System Exoenzyme S exoS + + + + +
Adenylate cyclase ExoY exoY + - + - -
Exoenzyme T exoT + + + + +
Exoenzyme U exoU - + - - +
Secreted regulator of type III secretion genes exse + + + + +
Type 4 Secretion System Amidase tse1 + + + + +
Type 4 secretion system effector tse2 + + + + +
Muramidase tse3 + + + + +
Pyoverdin vgrG + + + + +
3-oxo-C12-homoserine lactone acylase pvdQ + + + + +
Type 5 Secretion System Esterase estA + + + + +
Adhesive protein cupB5 + + + + +
Exoprotease lep + + + + +
Toxin/Antitoxin System Toxin/antitoxin system higA + + + + +
Toxin/antitoxin system higB + + + + +
Biofilm Alginate biosynthesis protein algX + + + + +
GDP-mannose 6-hydrogenase algD + + + + +
Poly(beta-d-mannuronate) lyase precursor algL + + + + +
Alkaline metalloproteinase precursor aprA + + + + +
Lectins Fructose-binding lectin PA-IIL lecB + + + + +
Neuramindases Pseudoaminidase nan1 + - + + +
Pseudoaminidase nan2 + + + + +
Quorum Sensing ProteinsAutoinducor synthesis protein lasL + + + + +
Transcriptional regulator lasR + + + + +
Rhamnolipids Autoinducor synthesis protein rhll + + + + +
Transcriptional regulator rhlR + + + + +
Flagella Flagellin type B fliC + - + + +
Polysaccharides Polysacharides psL + + + + +
Excreted factor Hydrogen cyanide HCN + + + + +
ExlA Secretion System Exolysin exlA - - - - -  
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Discussion 
 
The pathogenesis of P. aeruginosa is multifactorial as suggested by the large number of virulence 
determinants of this bacterium.  We have characterised the virulence gene profile of five BSI 
isolates by whole genome sequencing.  Almost complete conservation of the extensive set of  
virulence genes studied was seen.  Clinically these isolates were associated with rapid death in a 
susceptible host.  It may be that to cause an invasive infection in the setting of rapid host demise it 
is only the fittest isolate that succeeds.   
The characteristics of the larger patient cohort from which the five BSI episodes came from are 
described in detail [18]. This was a patient cohort with significant co-morbidities, predominantly 
cardiovascular or haematological in origin and in whom receipt of medical therapy in the preceding 
30 days occurred in 57% of the patients.  The most common therapy being either chemotherapy or 
corticosteroids [18].  Thus the patient characteristics of the five BSI episodes focused upon in this 
study have also been described in patients who did not die in the year post BSI.  We know from the 
literature that a higher Pitt score, as seen in patient three, predicts a high risk of death from the BSI 
[202]. Also that a lung source would be considered a high risk bacteraemia for mortality [162].  
However to put this in context of the larger cohort described, not all patients with a lung source of 
BSI died [18].  The empirical therapy was considered inadequate in four of the five BSI’s studied 
[18]. The importance of adequate empirical therapy is still debated in the setting of this infection in 
the literature [3, 29, 81].  As such although the patients described would be higher risk for death in 
the setting of this BSI, the BSI isolate must also play a role.   
The literature has focused on the type 3 protein secretion system (TTSS) and virulence in P. 
aeruginosa infections.  El-Sohl et al performed a retrospective analysis of 85 cases of P. aeruginosa 
BSI at a tertiary care hospital.  Bacterial isolates were assayed in vitro for secretion of type 3 
exotoxins.  They found that at least one of the TTSS proteins was detected in 37 of the 85 isolates 
(44%).  In addition the overall 30 day mortality was significantly greater on multivariate analysis in 
those isolates that were TTSS positive [203].  Pena et al looked at the genotypic relationship of the 
TTSS system in P. aeruginosa BSI’s and found a significant relationship between early mortality 
for the exoU genotype.  This was also associated with a moderately resistant susceptibility profile 
[114].  Only two of the five BSI isolates that were isolated from a patient with early mortality were 
exoU positive in the current study.   
Recently two other significant toxins as a cause of virulence in this pathogen have been described.  
A novel toxin exlA was also identified by Elsen et al, which induces plasma rupture in host cells 
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[199].  Reboud et al further studied 18 isolates, including one BSI isolate, that contained this toxin 
and was TTSS negative [115].  They found that the behaviour and virulence traits of the exlA+ 
strains were variable in the mouse and chicory leaf model [115].  Interestingly our isolates were 
negative for the exlA gene. This gene has not been found to be present in all clades of P. 
aeruginosa[204] Wood et al have also recently characterised the HigB/HigA toxin-antitoxin 
system.  The HigB toxin was shown to reduce pyocynanin, pyochelin, swarming and biofilm 
formation [116].  The higA and higB genes were found in all the BSI isolates studied.   
Focusing on acute infections caused by P. aeruginosa, limited numbers of genes related to 
pathogenicity have been described from different types of clinical isolates.  Consistent gene 
conservation has not been seen.  Faraji et al looked at burn wound isolates by targeted PCR and 
found that the prevelance rate of the virulence factors was as follows: toxA (36.9%), algD (70.1%), 
plcH (79%), plcN (63.1%), lasB (82%) and exoS (21.1%) [196].  Sebharwal et al looked at isolates 
from catheter associated urinary tract infections  by targeted PCR and found that the prevalence rate 
of virulence factors was toxA (100%), plcH (75%), lasB (75%), lasl (75%), lasR (75%), rhll 
(41.6%), rhlR (58.3%), aprA (16.6%), rhlAB (50%), fliC (58.3%) [197].  We found a high degree 
of conservation of the virulence genes in the BSI isolates studied.   It may be that to cause both a 
BSI and to be associated with rapid death that it is only the fittest isolate that succeeds.  Wolfgang 
et al looked at 18 P. aeruginosa strains from both the environment and clinical samples.  Two 
isolates of which were from blood.  Utilising whole-genome DNA microarray they found that upon 
examination of a gene set predicted to play a role in virulence, there was a high level of 
conservation (97%) [205].  Our study looking at BSI isolates supports this finding.   
The traditional view of P. aeruginosa pathogenicity was that virulence factors were the most 
important factors in the infective process.   Recent work by Turner et al involving translation 
research in mouse models has changed the thinking relating to virulence [1].  This study combined 
both mutant fitness profiling and transcriptome profiling to study which P. aeruginosa genes were 
important for acute or chronic infections.  For most classes of genes, including virulence genes, this 
analysis found that there was little association between transcript abundance and the contribution of 
the corresponding gene towards overall fitness.  However for certain metabolic genes these factors 
were strongly associated.  Interestingly it would seem that it is the environment that P. aeruginosa 
finds itself in that drives the metabolic pathways and subsequent expression of virulence factors as 
part of a process of survival.  This results in a variable virulence phenotype.  
Limitations of the current study include selection of the BSI episodes from a retrospective cohort 
study resulting in inherent biases in the patient group studied. In addition, patients had to be 
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admitted to hospital for antibiotic treatment to be included in the study and thus BSI episodes in 
which the patient died prior to hospitalisation would not have been considered for further analysis. 
Another limitation is the lack of correlation of phenotypic expression of virulence with the 
genotypic findings.  It would have been ideal if a larger selection of BSI isolates could have been 
studied.  Also comparison of the studied isolates to BSI isolates that were not associated with rapid 
patient death, other dominant clones from the Australian CF cohorts and overseas outbreak strains 
in CF cohorts would have allowed broader conclusions to be made from the work.  
In conclusion this study places the genotypic detection of virulence factors of P. aeruginosa BSI 
isolates in the clinical context.  Five P. aeruginosa BSI isolates that were associated with rapid 
patient mortality have had characterisation of their virulence gene profile.   There was extensive 
conservation of the 41 virulence genes studied across the isolates. Two of the isolates contained the 
exoU gene.  The higA and higB genes were detected in all isolates. The exlA gene was not detected 
in any of the isolates studied.  These findings may reflect that to cause both a BSI and rapid death 
that it is only the highly virulent P. aeruginosa isolate that succeeds.   
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5.3: Chapter Summary 
 
This chapter provides further insight into the virulence of P. aeruginosa.  An extensive range of 
virulence genes were studied and found to be present in all isolates that had caused BSI in the 
setting of early patient mortality.  Is this the required genotypic virulence of an isolate that is not 
only successful causing a BSI but also contributing to early patient death?  Further work looking at 
virulence genes in this setting is required. In addition, comparison of the genotypic virulence profile 
of BSI isolates that have and have not been associated with rapid patient death is a further area of 
research. 
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Chapter 6: Thesis Conclusion 
 
6.1: Conclusion 
 
The world is seeing an increasing prevalence of P. aeruginosa BSI in the context of little 
improvement in patient mortality [7].  P. aeruginosa has an ability to acquire resistance 
mechanisms and the spread of clones carrying different carbapenemase enzymes has been witnessed 
globally [46].  In an era where antibiotic development is lagging behind the resistance mechanisms 
we are presented with, we are unprepared.  It was therefore timely that this research further 
characterised the clinical and molecular epidemiology of this BSI and studied the genotypic 
virulence of this pathogen.   
The Australian epidemiology of P. aeruginosa BSI has been updated by this research.  The key 
differences described in comparison to the literature to date on P. aeruginosa BSI include: a non-
ICU setting for identification of patients with this BSI, lower severity of illness scores at the time of 
collection of the sentinel blood culture, lower rates of antibiotic resistance and lower patient 
mortality rates [18].  This work was the first to describe the unexpected increasing longitudinal 
mortality associated with P. aeruginosa BSI [18].  
The epidemiology of community acquired BSI changed with the sentinel paper by Friedman et al 
that introduced the classification of health care acquired infection [146].  The work in this thesis 
showed that some of the key factors upon which Friedman et al separated the original group of 
community acquired BSI into two acquisition groups including HCAI  did not apply in the setting 
of a P. aeruginosa BSI.  Community acquired P. aeruginosa BSI did not have a better clinical 
outcome, reduced antibiotic resistance or shorter inpatient stay in comparison to the health-care 
acquired infection group [19].   
Recurrent P. aeruginosa BSI had not been previously characterised in the literature.  This thesis 
found patient characteristics associated with the development of recurrent infection were a 
haematological malignancy and recent corticosteroid use. Recurrent BSI was found to place an 
individual at even higher risk of relapse and of mortality [20].    This work was expanded upon by 
further study of the molecular epidemiology of recurrent BSI isolates.    The recurrent BSI isolate 
was more likely to be the same genotype, the closer in time the recurrent BSI occurred after the 
primary BSI.  
Study of the molecular epidemiology of P. aeruginosa BSI isolates in a non-outbreak setting was 
also novel work  [21].  This work described the polyclonal population structure of P. aeruginosa 
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BSI isolates in the hospital setting.  Thus suggesting the presence of ongoing transmission and 
exposure to P. aeruginosa within the hospital environment.  This is potentially preventable and has 
infection control implications for the vulnerable host.   
The genotypic virulence of P. aeruginosa clinical isolates has been described in a limited fashion.  
The genotypic virulence of BSI isolates obtained from a host who experienced rapid death was 
novel work characterised in this thesis.  This is also one of the few studies to place the studied 
isolates in a clinical context.  Extensive conservation of the studied virulence genotype was seen. 
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6.2: Future Directions 
 
From this work there are a number of areas of future research that could be considered.  First the 
molecular typing of a greater range of P. aeruginosa clinical isolates could potentially give further 
insight into the route of hospital transmission and colonisation of the at risk patient.  Supplemented 
by selected environmental sampling this would allow key infection control interventions at the 
studied institution(s) to be focused on the high risk patients for this BSI.  
Secondly further research focused on attempting to understand how a P. aeruginosa BSI may 
contribute to long term patient mortality, in the non-septic patient, needs to occur. Consideration 
needs to be given to the development of an animal model to study this further.  
Thirdly further studies looking at treatment of this infection are required to better define if there are 
benefits of combination antibiotic therapy in the setting of P. aeruginosa BSI.  Combination 
antibiotic therapy theoretically has many advantages.  However recent studies have not consistently 
shown an outcome benefit for P. aeruginosa BSI [17, 99, 100].   
Fourthly the knowledge of the virulence of BSI isolates could be expanded by looking at a greater 
number of BSI isolates in the clinical context.  Particularly comparator BSI isolates that have not 
been associated with rapid patient death or other characterised strains from alternate models of 
infection.  Correlation with studies of phenotypic virulence with utilisation of Ribonucleic acid 
(RNA) -sequencing could also be performed. The provision of whole genome transcriptional 
profiles under different growth and environmental conditions as described by Dotsch et al would be 
potentially enlightening [206].  Due to factors such as RNA stability, translational efficiency and 
post translational regulation, proteomics is also important to look at encoded products which don’t 
always correlate with RNA expression. Such an approach was demonstrated by Grady et al who 
looked at the effect of n-alkanes in comparison to glycerol on P. aeruginosa growth [207].   These 
techniques could for example, be used to compare isolates from different sites of infection or 
isolates from patients with and without sepsis.  
Fifthly knowledge of how P. aeruginosa manipulates host cells to cause morbidity and mortality is 
increasing and provides opportunity for the development of therapeutic agents that target virulence 
mechanisms. Bomberger et al provided further understanding into outer membrane vesicles that 
allow the long distance carriage of multiple virulence factors which are delivered directly into the 
host cytoplasm [208]. These vesicles have also been found to have  a role in enabling bacterial 
survival during stress conditions and regulation of microbial interactions with bacterial 
communities such as a biofilm [209]. Quorum sensing is another regulatory network that 
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orchestrates gene expression that underlies collective behaviours. O’Loughlin et al described meta-
bromo-thiolactone, a small molecule that inhibited quorum- sensing receptor RhlR [210].   Betulin 
and Betulinic acid have also been shown to be successful in inhibiting quorum sensing receptors 
[211]. P aeruginosa biofilms display characteristic features such as different morphology and 
physiology.  Antibiotic and immune system resistance is also seen.  Therapeutic targets that are 
being studied to eradicate biofilms include targeting adhesion, maturation, dispersal and virulence 
factors [212].  Such knowledge may also be utilised to develop more complex laboratory models for 
the study of human infection. .  
Finally we now have greater understanding of the properties of the human microbiota and the host-
microbiota interactions.  One important role of this flora is colonisation resistance, although the 
molecular basis of this is still to be determined. There is also linkage of the gut microbiota with 
immune homeostasis [213].  Deep sequencing has allowed greater understanding of the complexity 
of the microbiota at different body sites including the lung.  Different lung disease states have been 
shown to have different microbiota and inflammation in the airway alters airway growth conditions. 
This results in a disordered microbiota that through metabolite signalling and other pathways 
provokes further airway inflammation [214].  This growing area of knowledge may help advance 
models of infection and also enable us to develop ways of manipulating the host’s microbiota to his 
or her advantage as part of the treatment of their infection.  
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                Patient Name:  ___________________   Name of person completing form: ______________ 
                DOB:   /    /          Date completed:      /       / 
                UR : ___________________ 
 
 
 
 
                 Pseudomonas aeruginosa Bacteraemia Form 
 
 
 Date of collection of first positive blood culture (blood culture 1) with P. aeruginosa:   ___/___/___  Time_______ 
         
  Did lab processing time have to be used no other documentation available?  Y  /N               
 
DEMOGRAPHICS: 
 
Age at time of first positive blood culture: ____yrs      Sex:  Male    Female 
 
Race:  Caucasian   Aboriginal/Islander  Asian    Other (specify): _________                  
 
 
 
ACQUISITION: 
 
Date of hospital admission:   ___/___/___ 
Hospital of admission:   GPH   MPUB MPR   PAH    PCH   RBH   WH  SAH 
 
            
 Hospital-acquired 
 Healthcare-associated   
 Community-associated 
  
 
RISK FACTORS: 
 
Underlying Disease at admission and subsequently diagnosed up until 48 hours prior to date first positive blood 
culture was taken 
 
Please circle.   
 
 
CNS disease   Type________                                           Cardiovascular disease  Type_________                                                      
Pulmonary disease    Type________                             Hepatobiliary  disease  Type_________  
                 Kidney disease  Type________                             Urinary Tract disease   Type ________ 
                 Gastrointestinal disease  Type__________                  Rheumatological condition   Type______  
Autoimmune disease  Type _______                        Skin and soft tissue  Type ________ 
 Haematological condition  Type________             Oncological malignancy Type_______ 
               Diabetes                                                                             Organ transplant   Type_______Date______ 
              HIV                                                                                                                                                             
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Presence of a medical device in the 7 days prior to the date of collection of the first positive blood culture: 
 
 
o CSF pressure monitoring device 
o Tracheostomy tube       
o Endotracheal tube                                                                  
o Vascular catheter (e.g. PICC, vascath, CVC, port, peripheral cannula), specify ___________ 
o Pacemaker 
o ECCMO 
o Gastrostomy tube(PEG) 
o Ileostomy or colostomy 
o Indwelling urinary catheter 
o Prosthesis or foreign material  Type_______   Site________  
 
 
 
Therapy within the 30 days prior to the date of collection of the first positive blood culture: 
 
o Chemotherapy, specify __________________________________________ 
o Oral or intravenous corticosteroids 
o TNF blocker (in the last year) specify and date of administration _________________ 
o Other immunosuppressive therapy, specify________________________________________ 
o Radiation therapy 
o Blood product transfusion, specify____________________________ 
o TPN 
 
 
Other Risk Factors:  
 
 
1. Neutropenia (Absolute neutrophil count <0.5 x 10 9/L) in the 14 days prior to or after the date of collection of 
the first positive blood culture  
 Y / N 
Date of onset         /  /     
Date of resolution  (ANC >/= 0.5 x 10 9/L)           /   / 
Length of neutropenia (days)____ 
 
2. Prior surgery within the 14 days prior to the date of collection of the first positive blood culture 
Y  /  N 
Type        __________________ 
Date             /   / 
 
 
PRESUMED SOURCE OF BACTEREMIA:  
o CNS 
o Mastoiditis 
o Pneumonia  
o Intra-abdominal infection  Type________ 
o Mucositis 
o Urinary tract infection 
o Line related infection 
o Musculoskeletal 
o Skin and soft tissue infection including burns   Type ________ 
o Surgical site infection  
o Other; please specify: ____________ 
o Unknown 
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ANTIMICROBIALS STARTED > 48HRS BEFORE BACTEREMIA: 
 
 
 
Up to 30 days prior to enrolment.  Please order data in chronological order if possible. 
 
Prior allergy to antibiotics:  No   Yes; specify: ____________, ______________, _______________ 
 
 
 
 
 
 
 
ANTIMICROBIALS STARTED WITHIN 48HRS AND AFTER BACTEREMIA: 
 
 
 
  Up to 30 days after enrolment.  Please order data in chronological order if possible. 
 
Antimicrobial Dose/route/frequency Starting date Starting 
Time     
time 
Ending date Last dose 
Tim     
time 
e.g. cefepime 1gm iv q12h 17/10/2006  2000 27/10/2006  0800 
            
            
            
            
            
            
            
            
            
            
 
 
 
 
 
 
 
 
Antimicrobial Dose/route/frequency Starting date Starting 
Time    
time 
Ending date Last dose 
Time    
time 
e.g. cefepime 1gm iv q12h 17/10/2006  2000 27/10/2006  0800 
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DAILY MONITORING: 
 
Start on the day of collection of the first positive blood culture for P. aeruginosa (for 14 sequential days) 
 
 
Date ___/__
_ 
___/___ ___/___ ___/___ ___/___ ___/___ ___/___ ___/___ ___/___ ___/___ ___/___ ___/___ ___/___ ___/___ 
Tmax               
WCC               
SBP lowest               
Pressor               
 
 
 
 
 
 
ILLNESS SCORE:   
 
 
To performed on patient data collected 48 hours prior to the date of collection of the first positive P. aeruginosa 
blood culture.  Perform both the Charlson comorbidity index and the Pitt bacteremia score.  
If the patient was an outpatient at this time, data collection should be taken from the variables at admission.   
 
 
 
Charlson Comorbidity Index 
See Table in Definition 
Please circle if present 
 
Myocardial infarct                                        Hemiplegia 
Congestive heart failure                             Moderate or severe renal disease 
Peripheral vascular disease                      Diabetes with end organ damage 
Cerebrovascular disease                            Any tumor 
Dementia                                                         Leukaemia 
Chronic pulmonary disease                       Lymphoma 
Connective tissue disease                           Moderate or severe liver disease 
Ulcer disease                                                   Metastatic solid tumor 
Mild liver disease                                          Acquired immunodefieciency syndrome 
Diabetes 
  
SCORE =     / 37 
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Pitt Bacteremia Score 
 
 
 
Score =     /14 
 
 
 
 
 
DISCHARGE & IN HOSPITAL MORTALITY:  
Was a not for resuscitation order placed on this patient during the admission?    Y  or   N    
 
Date of hospital discharge  ___/___/___    or      Date of death    /    /     
 
Length of stay post date of first positive blood culture for P. aeruginosa   _____ days 
 
  7 days post first positive P. aeruginosa blood culture is the patient:     alive   or   dead 
                                           
  28 days post first positive P. aeruginosa blood culture is the patient:     alive   or   dead 
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MICROBIOLOGY:  
 
P. aeruginosa Blood Cultures 
Only include one blood culture per day ie if multiple sets taken on a particular day – record 1 set only. If more than 3 
days of positive blood culture to be recorded please continue on a new form.   
                 
    
Blood Culture 1 
 
Date/time of the culture drawn : ___/___/___,      ___:___ 
 
Site of the culture drawn:  peripheral     other (specify): __________ 
 
Location of patient at time of collection:  O/P    Emergency    Ward     ICU 
 
Laboratory _____   Lab number_______________ 
 
 
O.K. to attach a copy of the susceptibility report instead of filling the table 
 
Antimicrobial MIC/zone size S/I/R Antimicrobial MIC/zone size S/I/R 
Amikacin     Aztreonam     
Cefepime     Ceftazidime     
Ciprofloxacin     Colistin     
Gentamicin     Doripenem     
Meropenem 
 
    Piperacillin-
Tazobactam 
    
Piperacillin 
Ticarcillin-Clavulanate     Tobramycin     
 
 
Concomitant organisms* on the same blood culture:  Y or N 
 
Organism: ________________________  
Organism:_________________________ 
 
Other sites of growth of P. aeruginosa within 48 hours before or after the blood culture: 
Sputum      
Endotracheal aspirate 
Bronchoalveolar lavage 
Intra-abdominal site, specify: _______________ 
Urine: ________________ CFU/ml 
Central line tip: _________________ CFU 
Other: _________________________________________________ 
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Blood Culture 2 
 
 
Date/time of the culture drawn : ___/___/___,      ___:___ 
 
Site of the culture drawn:  peripheral   other (specify): __________ 
 
Laboratory _____   Lab number_______________ 
 
 
O.K. to attach a copy of the susceptibility report instead of filling the table. Please mark which number blood culture 
print out refers to. 
 
 
Antimicrobial MIC/zone size S/I/R Antimicrobial MIC/zone size S/I/R 
Amikacin     Aztreonam     
Cefepime     Ceftazidime     
Ciprofloxacin     Colistin     
Gentamicin     Doripenem     
Meropenem 
 
    Piperacillin-
Tazobactam 
    
Piperacillin 
Ticarcillin-Clavulante     Tobramycin     
 
 
 
Concomitant organisms* on the same blood culture:  Y or N 
 
Organism: ________________________  
Organism:_________________________ 
 
 
Other sites of growth of P. aeruginosa within 48 hours before or after the blood culture: 
 
Sputum     
Endotracheal aspirate 
Bronchoalveolar lavage 
Intra-abdominal site, specify: _______________ 
Urine: ________________ CFU/ml 
Central line tip: _________________ CFU 
Other: _________________________________________________ 
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Blood Culture 3 
 
Date/time of the culture drawn : ___/___/___,      ___:___ 
 
Site of the culture drawn:  peripheral   other (specify): __________ 
 
Laboratory _____   Lab number_______________ 
 
 
O.K. to attach a copy of the susceptibility report instead of filling the table. Please mark which number blood culture 
print out refers to. 
 
Antimicrobial MIC/zone size S/I/R Antimicrobial MIC/zone size S/I/R 
Amikacin     Aztreonam     
Cefepime     Ceftazidime     
Ciprofloxacin     Colistin     
Gentamicin     Doripenem     
Meropenem 
 
    Piperacillin-
Tazobactam 
    
Piperacillin 
Ticarcillin-Clavulanate     Tobramycin     
 
 
 
 
Concomitant organisms* on the same blood culture:  Y or N 
 
Organism: ________________________  
Organism:_________________________ 
 
 
Other sites of growth of P.aeruginosa within 48 hours before or after the blood culture: 
 
Sputum      
Endotracheal aspirate 
Bronchoalveolar lavage 
Intra-abdominal site, specify: _______________ 
Urine: ________________CFU/ml  
Central line tip: _________________ CFU 
Other: _________________________________________________ 
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P. aeruginosa Bacteremia Clearance: 
 
 
 
Please list all blood cultures taken culturing P. aeruginosa even if on the same day.  Up to 30 days from first positive P. 
aeruginosa blood culture; mark + if at least one culture is positive, – if all cultures are negative-  
 
 
Date (MM/DD)   _ /_ /_ _ /_ /_ _ /_ /_ _ /_ /_ _ /_ /_ _ /_ / _ _ /_ /_  _ /_ / _ 
Time                  
Blood culture +               
Date (MM/DD) _ /_ /_ _ /_ / _ _ /_ / _ _ /_ /_ _ /_ /_  _ /_ /_  _ /_ / _ _ /_ / _ 
Time                  
Blood culture                 
 
 
 
 
 
Other Positive Blood Cultures: 
 
Y or N 
 
From 10 days prior to first positive blood culture with P. aeruginosa to 14 days after last positive blood culture with P. 
aeruginosa 
 
Date Collected Site Organism 1 Organism 2 Organism 3  
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